Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
1(3)-arachidonoylglycerol + H2O
? + glycerol
-
-
-
?
1(3)-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
1,3-dihydroxypropan-2-yl 4-pyren-1-ylbutanoate
pyrenylbutanoic acid + glycerol
1,3-dihydroxypropan-2-yl 4-pyren-1-ylbutanoate + H2O
pyrenylbutanoic acid + glycerol
-
-
-
-
?
1-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
-
?
1-arachidonoylglycerol + H2O
glycerol + arachidonic acid
1-capryloyl-rac-glycerol + H2O
glycerol + caprylic acid
-
-
-
-
?
1-decanoyl-rac-glycerol + H2O
glycerol + decanoic acid
1-lauroyl-rac-glycerol + H2O
glycerol + lauric acid
1-linoleoylglycerol + H2O
glycerol + linoleic acid
-
-
-
-
?
1-mono-oleyl-rac-glycerol + H2O
oleate + glycerol
-
-
-
-
?
1-monobutyroyl-rac-glycerol + H2O
butyrate + glycerol
-
-
-
-
?
1-monocaprylin + H2O
?
-
-
-
-
?
1-monocapryloylglycerol + H2O
caprylic acid + glycerol
1-monodecanoyl-rac-glycerol + H2O
decanoate + glycerol
-
-
-
-
?
1-monolauroyl-rac-glycerol + H2O
laureate + glycerol
-
-
-
-
?
1-monolauroylglycerol + H2O
lauric acid + glycerol
1-monolinolein + H2O
?
-
one of the most preferred substrates
-
-
?
1-monolinolenin + H2O
?
-
best substrate
-
-
?
1-monolinoleoylglycerol + H2O
linolic acid + glycerol
-
-
-
?
1-monolinoleoylycerol + H2O
linoleic acid + glycerol
-
-
?
1-monomyristoyl-rac-glycerol + H2O
myristoate + glycerol
-
-
-
-
?
1-monomyristoylglycerol + H2O
myristic acid + glycerol
1-monooctanoyl-rac-glycerol + H2O
octanoate + glycerol
-
-
-
-
?
1-monoolein + H2O
?
-
one of the most preferred substrates
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
1-monopalmitin + H2O
?
-
-
-
-
?
1-monopalmitoylglycerol + H2O
palmitic acid + glycerol
1-monostearoylglycerol + H2O
stearic acid + glycerol
-
-
?
1-myristoyl-rac-glycerol + H2O
glycerol + myristic acid
-
-
-
-
?
1-oleoyl-glycerol + H2O
oleate + glycerol
1-oleoyl-rac-glycerol + H2O
glycerol + oleic acid
1-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
1-palmitoyl-2-lysophosphatidylcholine + H2O
palmitic acid + glycerophosphorylcholine
-
-
-
-
?
2-(15-deoxy-DELTA12,14-prostaglandin J2)-glycerol + H2O
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
2-arachidonoylglycerol + H2O
arachidonoate + glycerol
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
2-linoleoylglycerol + H2O
glycerol + linoleic acid
-
-
-
-
?
2-monolinolein + H2O
?
-
-
-
-
?
2-monomyristoylglycerol + H2O
myristic acid + glycerol
-
-
-
-
?
2-monooleoylglycerol + H2O
oleic acid + glycerol
2-monopalmitoylglycerol + H2O
palmitic acid + glycerol
-
-
-
-
?
2-oleoylglycerol + H2O
glycerol + oleic acid
-
-
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
2-palmitoylglycerol + H2O
glycerol + palmitic acid
-
-
-
-
?
3-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
4-methylumbelliferyl butyrate + H2O
4-methylumbelliferol + butyrate
-
-
-
?
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
4-nitrophenyl butyrate + H2O
4-nitrophenol + butyric acid
-
-
?
4-nitrophenyl caprate + H2O
4-nitrophenol + capric acid
-
-
?
4-nitrophenyl caprylate + H2O
4-nitrophenol + caprylic acid
-
-
?
4-nitrophenyl octanoate + H2O
4-nitrophenol + octanoate
-
-
?
4-nitrophenyl-caproate + H2O
4-nitrophenol + caproic acid
-
-
?
4-nitrophenyl-laurate + H2O
4-nitrophenol + lauric acid
-
-
?
4-nitrophenyl-myristate + H2O
4-nitrophenol + myristic acid
-
-
?
4-nitrophenyl-palmitate + H2O
4-nitrophenol + palmitic acid
-
-
?
4-nitrophenyl-stearate + H2O
4-nitrophenol + stearic acid
-
-
?
4-nitrophenyllaurate + H2O
4-nitrophenol + lauric acid
7-hydroxycoumarinyl arachidonate
arachidonic acid + 7-hydroxycoumarin
-
-
-
-
?
7-hydroxycoumarinyl arachidonate + H2O
7-hydroxycoumarin + arachidonate
7-hydroxyresorufinyl arachidonate + H2O
7-hydroxyresorufin + arachidonate
a red fluorogenic substrate, 7-HRA, that is stable in 10% DMSO for at least 36 h at room temperature and for at least 6 months at 4°C, synthesis, overview
-
-
?
arachidonoyl-1-thio-glycerol + H2O
?
arachidonoyl-7-hydroxy-6-methoxy-4-methylcoumarin ester + H2O
arachidonic acid + 7-hydroxy-6-methoxy-4-methylcoumarin
bis(monoacylclycerol) phosphate + H2O
?
-
at pH 5.5
-
?
ethyl oleate + H2O
oleic acid + ethanol
-
-
-
-
?
glycerol + lauric acid
monolaurin + H2O
-
93% conversion after 6 h
-
-
r
glycerol + myristic acid
monomyristin + H2O
-
60% conversion after 6 h
-
-
r
glycerol + oleic acid
monoolein + H2O
-
46% conversion after 6 h
-
-
r
glycerol + palmitic acid
monopalmitin + H2O
-
50% conversion after 6 h
-
-
r
glycerol + stearic acid
monostearin + H2O
-
60% conversion after 6 h
-
-
r
lauric acid + glycerol
monolauroyl glycerol + H2O
-
catalyzes the esterification of lauric acid and glycerol in a homogeneous system, minimal amounts of dilaurin are also synthesized
-
?
lysobisphosphatidic acid + H2O
?
-
at pH 5.5
-
?
lysophosphatidylcholine + H2O
fatty acid + glycerophosphocholine
-
-
-
?
lysophosphatidylethanolamine + H2O
fatty acid + glycerophosphoethanolamine
-
-
-
?
methyl butyrate + H2O
methanol + butanoate
-
-
-
-
?
methylcaprylate + H2O
?
-
low activity
-
-
?
methyloleate + H2O
?
-
low activity
-
-
?
monoacylglycerol + H2O
acylic acid + glycerol
monoacylglycerol + H2O
fatty acid + glycerol
-
-
-
?
monoarachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
?
monolinoleoylglycerol + H2O
linoic acid + glycerol
monomyristin + H2O
glycerol + myristate
monomyristoylglycerol + H2O
myristic acid + glycerol
-
-
-
?
monoolein + H2O
glycerol + oleate
monooleoylglycerol + H2O
oleic acid + glycerol
monostearoylglycerol + H2O
stearic acid + glycerol
palmitoyl-CoA + H2O
palmitic acid + CoA
-
-
-
-
?
phosphatidylcholine + H2O
?
prostaglandin D2-G + H2O
?
-
-
-
-
?
prostaglandin D2-glycerol + H2O
?
prostaglandin E2-G + H2O
?
-
-
-
-
?
prostaglandin E2-glycerol + H2O
?
prostaglandin F2alpha-glycerol + H2O
?
-
-
-
?
prostaglandin F3alpha-G + H2O
?
-
-
-
-
?
rac-1(3)-oleoylglycerol + H2O
oleate + glycerol
-
-
-
-
?
sn-2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
sn-2-monoolein + H2O
glycerol + oleic acid
sn-2-palmitoylglycerol + H2O
palmitic acid + glycerol
-
-
-
-
?
tributyrylglycerol + H2O
?
-
-
-
-
?
trieicosapentaenoin + H2O
?
-
low activity
-
-
?
trilaurin + H2O
?
-
low activity
-
-
?
trilinolein + H2O
?
-
low activity
-
-
?
trilinolenin + H2O
?
-
low activity
-
-
?
tripalmitin + H2O
?
-
-
-
-
?
tripalmitolein + H2O
?
-
-
-
-
?
tristearin + H2O
?
-
-
-
-
?
umbelliferyl arachidonate + H2O
umbelliferol + arachidonic acid
-
-
-
?
additional information
?
-
1,2-dicaprin + H2O
?
-
-
-
-
?
1,2-dicaprin + H2O
?
-
-
-
-
?
1,3-dihydroxypropan-2-yl 4-pyren-1-ylbutanoate
pyrenylbutanoic acid + glycerol
-
-
-
-
?
1,3-dihydroxypropan-2-yl 4-pyren-1-ylbutanoate
pyrenylbutanoic acid + glycerol
-
-
-
-
?
1-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
-
?
1-arachidonoylglycerol + H2O
glycerol + arachidonic acid
best substrate
-
-
?
1-decanoyl-rac-glycerol + H2O
glycerol + decanoic acid
-
-
-
?
1-decanoyl-rac-glycerol + H2O
glycerol + decanoic acid
-
best substrate
-
-
?
1-lauroyl-rac-glycerol + H2O
glycerol + lauric acid
more than 2fold higher activity compared to 1-oleoly-rac-glycerol
-
-
?
1-lauroyl-rac-glycerol + H2O
glycerol + lauric acid
more than 2fold higher activity compared to 1-oleoly-rac-glycerol
-
-
?
1-lauroyl-rac-glycerol + H2O
glycerol + lauric acid
-
-
-
-
?
1-monocapryloylglycerol + H2O
caprylic acid + glycerol
best substrate
-
?
1-monocapryloylglycerol + H2O
caprylic acid + glycerol
best substrate
-
?
1-monolauroylglycerol + H2O
lauric acid + glycerol
-
best substrate
-
?
1-monolauroylglycerol + H2O
lauric acid + glycerol
good substrate
-
?
1-monolauroylglycerol + H2O
lauric acid + glycerol
-
best substrate
-
?
1-monolauroylglycerol + H2O
lauric acid + glycerol
good substrate
-
?
1-monomyristoylglycerol + H2O
myristic acid + glycerol
good substrate
-
?
1-monomyristoylglycerol + H2O
myristic acid + glycerol
good substrate
-
?
1-monomyristoylglycerol + H2O
myristic acid + glycerol
-
best substrate
-
r
1-monomyristoylglycerol + H2O
myristic acid + glycerol
-
best substrate
-
r
1-monomyristoylglycerol + H2O
myristic acid + glycerol
-
-
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
1-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
1-monopalmitoylglycerol + H2O
palmitic acid + glycerol
-
-
?
1-monopalmitoylglycerol + H2O
palmitic acid + glycerol
-
-
?
1-monopalmitoylglycerol + H2O
palmitic acid + glycerol
-
-
-
r
1-monopalmitoylglycerol + H2O
palmitic acid + glycerol
-
-
-
r
1-monopalmitoylglycerol + H2O
palmitic acid + glycerol
-
-
-
-
?
1-oleoyl-glycerol + H2O
oleate + glycerol
-
-
-
?
1-oleoyl-glycerol + H2O
oleate + glycerol
-
-
-
?
1-oleoyl-glycerol + H2O
oleate + glycerol
-
-
-
?
1-oleoyl-rac-glycerol + H2O
glycerol + oleic acid
-
-
-
?
1-oleoyl-rac-glycerol + H2O
glycerol + oleic acid
-
-
-
?
2-(15-deoxy-DELTA12,14-prostaglandin J2)-glycerol + H2O
?
-
-
-
-
?
2-(15-deoxy-DELTA12,14-prostaglandin J2)-glycerol + H2O
?
highest preference
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
the enzyme is responsible for degradation of 2-arachidonoylglycerol in HeLa cells
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
MGL modulates endocannabinoid signaling in vivo by inactivating 2-arachidonoylglycerol (2-AG), the main endogenous agonist for central CB1 and peripheral CB2 cannabinoid receptors
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
2-arachidonoylglycerol is bound in the tetrahedral intermediate state to Ser122
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
the MGL binding site is a single hydrophobic channel, consisting of an L-shaped main channel with a sub-pocket at the turn. The catalytic S122 of MGL is positioned at the bottom of a single channel
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
2-arachidonoylglycerol is an endocannabinoid which prevents the propagation of harmful neuroinflammation and may function as a gliotransmitter
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
the enzyme is responsible for degradation of 2-arachidonoylglycerol in the brain
-
-
?
2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonoate + glycerol
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonoate + glycerol
-
-
-
?
2-arachidonoylglycerol + H2O
arachidonoate + glycerol
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
presynaptic MGL not only hydrolyzes 2-arachidonoylglycerol released from activated postsynaptic neurons but also contributes to degradation of constitutively produced 2-arachidonoylglycerol and prevention of its accumulation around presynaptic terminals. Thus, the MGL activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
more than 80% of 2-arachidonoylglycerol (0.05 mM) is hydrolyzed after 90 min in the presence of 0.02 mg of MAGL(+/+) brain extracts at room temperature
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
presynaptic MGL not only hydrolyzes 2-arachidonoylglycerol released from activated postsynaptic neurons but also contributes to degradation of constitutively produced 2-arachidonoylglycerol and prevention of its accumulation around presynaptic terminals. Thus, the MGL activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
-
-
-
?
2-arachidonoylglycerol + H2O
glycerol + arachidonic acid
-
presynaptic MGL not only hydrolyzes 2-arachidonoylglycerol released from activated postsynaptic neurons but also contributes to degradation of constitutively produced 2-arachidonoylglycerol and prevention of its accumulation around presynaptic terminals. Thus, the MGL activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus
-
-
?
2-monoolein + H2O
?
-
-
-
-
?
2-monoolein + H2O
?
-
-
-
-
?
2-monoolein + H2O
?
-
-
-
-
?
2-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
2-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
2-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
2-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
r
2-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
r
2-monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
-
Cys208 plays an important role in MGL function
-
-
?
2-oleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
-
-
-
?
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
-
-
-
-
?
4-nitrophenyl acetate + H2O
4-nitrophenol + acetate
-
-
-
?
4-nitrophenyllaurate + H2O
4-nitrophenol + lauric acid
-
-
-
?
4-nitrophenyllaurate + H2O
4-nitrophenol + lauric acid
-
-
-
r
4-nitrophenyllaurate + H2O
4-nitrophenol + lauric acid
-
-
-
r
4-nitrophenyllaurate + H2O
4-nitrophenol + lauric acid
-
-
-
?
7-hydroxycoumarinyl arachidonate + H2O
7-hydroxycoumarin + arachidonate
-
-
-
?
7-hydroxycoumarinyl arachidonate + H2O
7-hydroxycoumarin + arachidonate
-
-
-
?
7-hydroxycoumarinyl arachidonate + H2O
7-hydroxycoumarin + arachidonate
fluorescence detection using a fluorogenic probe 1,3-dihydroxypropan-2-yl-4-pyren-1-ylbutanoate
-
-
?
arachidonoyl-1-thio-glycerol + H2O
?
-
-
-
?
arachidonoyl-1-thio-glycerol + H2O
?
-
-
-
?
arachidonoyl-7-hydroxy-6-methoxy-4-methylcoumarin ester + H2O
arachidonic acid + 7-hydroxy-6-methoxy-4-methylcoumarin
-
-
-
-
?
arachidonoyl-7-hydroxy-6-methoxy-4-methylcoumarin ester + H2O
arachidonic acid + 7-hydroxy-6-methoxy-4-methylcoumarin
-
-
-
?
diolein + H2O
?
-
-
-
-
?
diolein + H2O
?
-
-
-
-
?
monoacylglycerol + H2O
acylic acid + glycerol
-
-
-
?
monoacylglycerol + H2O
acylic acid + glycerol
-
-
-
?
monolinoleoylglycerol + H2O
linoic acid + glycerol
-
-
-
?
monolinoleoylglycerol + H2O
linoic acid + glycerol
-
-
-
?
monolinoleoylglycerol + H2O
linoic acid + glycerol
-
-
-
?
monomyristin + H2O
glycerol + myristate
-
-
-
-
?
monomyristin + H2O
glycerol + myristate
-
-
-
-
?
monoolein + H2O
glycerol + oleate
-
-
-
-
?
monoolein + H2O
glycerol + oleate
-
-
-
-
?
monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
monooleoylglycerol + H2O
oleic acid + glycerol
-
preferred substrate
-
-
?
monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
-
?
monooleoylglycerol + H2O
oleic acid + glycerol
-
-
-
?
monostearoylglycerol + H2O
stearic acid + glycerol
-
-
-
?
monostearoylglycerol + H2O
stearic acid + glycerol
-
-
-
?
monostearoylglycerol + H2O
stearic acid + glycerol
-
-
-
?
phosphatidylcholine + H2O
?
-
one of the most preferred substrates
-
-
?
phosphatidylcholine + H2O
?
-
one of the most preferred substrates
-
-
?
prostaglandin D2-glycerol + H2O
?
-
-
-
-
?
prostaglandin D2-glycerol + H2O
?
-
-
-
?
prostaglandin E2-glycerol + H2O
?
-
-
-
-
?
prostaglandin E2-glycerol + H2O
?
-
-
-
?
sn-2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
-
?
sn-2-arachidonoylglycerol + H2O
arachidonic acid + glycerol
-
-
-
?
sn-2-monoolein + H2O
glycerol + oleic acid
-
-
-
-
?
sn-2-monoolein + H2O
glycerol + oleic acid
-
-
-
-
?
sn-2-monoolein + H2O
glycerol + oleic acid
-
-
-
-
?
soybean oil + H2O
?
-
-
-
-
?
soybean oil + H2O
?
-
-
-
-
?
tricaprylin + H2O
?
-
-
-
-
?
tricaprylin + H2O
?
-
-
-
-
?
triolein + H2O
?
-
the lipase strongly hydrolyzes the sn-1/3 ester bonds and weakly hydrolyzes the sn-2 ester bonds of triolein
-
-
?
triolein + H2O
?
-
the lipase strongly hydrolyzes the sn-1/3 ester bonds and weakly hydrolyzes the sn-2 ester bonds of triolein
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL16 (AtMAGL16) shows very weak lipase activity. AtMAGL16 may not be involved in the hydrolysis of lipid substrates
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL16 (AtMAGL16) shows very weak lipase activity. AtMAGL16 may not be involved in the hydrolysis of lipid substrates
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL16 (AtMAGL16) shows very weak lipase activity. AtMAGL16 may not be involved in the hydrolysis of lipid substrates
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL6 (AtMAGL6) shows strong lipase activity
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL6 (AtMAGL6) shows strong lipase activity
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL6 (AtMAGL6) shows strong lipase activity
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL8 (AtMAGL8) shows strong lipase activity
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL8 (AtMAGL8) shows strong lipase activity
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays. The Arabidopsis thaliana isozyme MAGL8 (AtMAGL8) shows strong lipase activity
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL1 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL10 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL11 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL14 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL15 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL16 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozymes regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL2 is active with monoacylglycerol and lysophosphatidylethanolamine substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylcholine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL3 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL4 is active with monoacylglycerol, lysophosphatidylcholine, and lysophosphatidylethanolamine substrates, but not with diacylglycerol, and triacylglycerol substrates as well as with monogalactosyldiacylglycerol and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL5 is inactive with monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL6 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL7 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL8 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
usage of various lipid substrates containing 18:2 fatty acids at the sn-1 (monoacylglycerol, diacylglycerol, triacylglycerol, lysophosphatidylcholine, lysophosphatidylethanolamine, monogalactosyldiacylglycerol, and digalactosyldiacylglycerol), sn-2 (triacylglycerol and digalactosyldiacylglycerol), and sn-3 (diacylglycerol, triacylglycerol) positions. Isozyme AtMAGL9 is active with monoacylglycerol substrates, but not with diacylglycerol, triacylglycerol, lysophosphatidylethanolamine, and lysophosphatidylcholine substrates. Isozyme regiospecificities and substrate specificities, specificities for monoacylglycerols with various fatty acids at sn-1 position, overview
-
-
?
additional information
?
-
-
hydrolyzes monoacylglycerols but not di- or triacylglycerols
-
?
additional information
?
-
preferentially hydrolyzes triacylglycerol-esters and 4-nitrophenyl-esters of fatty acids with short chain lengths up to 10 carbon atoms, no hydrolysis of triolein
-
?
additional information
?
-
-
preferentially hydrolyzes triacylglycerol-esters and 4-nitrophenyl-esters of fatty acids with short chain lengths up to 10 carbon atoms, no hydrolysis of triolein
-
?
additional information
?
-
-
hydrolyzes monoacylglycerols but not di- or triacylglycerols
-
?
additional information
?
-
-
developmental and nutritional regulation of the enzyme in the intestine, overview
-
-
?
additional information
?
-
-
key enzyme responsible for the termination of endocannabinoid signaling with a crucial role in 2-arachidonoylglycerol metabolism, MAGL is unable to mediate anandamide degradation, overview
-
-
?
additional information
?
-
direct NMR detection of a reversible equilibrium between active and inactive states of human MGL (hMGL) that is slow on the NMR time scale and can be modulated in a controlled manner by pH, temperature, and select point mutations
-
-
?
additional information
?
-
-
direct NMR detection of a reversible equilibrium between active and inactive states of human MGL (hMGL) that is slow on the NMR time scale and can be modulated in a controlled manner by pH, temperature, and select point mutations
-
-
?
additional information
?
-
human monoacylglycerol lipase (MAGL) displays catalytic activity on monoacyl glycerols with medium to long-chain lipophylic moieties such as stearoyl, palmitoyl, oleoyl, and especially arachidonoyl groups. MAGL also demonstrates preference for the hydrolysis of 2-acyl glycerols over their 1(3)-regioisomers. Measurement of MAGL-catalyzed hydrolysis of p-nitrophenyl alkyl esters by monitoring the liberation of p-nitrophenol. Fluorogenic enzyme assay method evaluation, overview
-
-
?
additional information
?
-
-
human monoacylglycerol lipase (MAGL) displays catalytic activity on monoacyl glycerols with medium to long-chain lipophylic moieties such as stearoyl, palmitoyl, oleoyl, and especially arachidonoyl groups. MAGL also demonstrates preference for the hydrolysis of 2-acyl glycerols over their 1(3)-regioisomers. Measurement of MAGL-catalyzed hydrolysis of p-nitrophenyl alkyl esters by monitoring the liberation of p-nitrophenol. Fluorogenic enzyme assay method evaluation, overview
-
-
?
additional information
?
-
usage of a substrate with linoleic acid at the sn-1 position for enzyme activity assays
-
-
?
additional information
?
-
-
monoacylglycerols containing long-chain unsaturated fatty acids and phosphatidylcholine are preferentially hydrolyzed over triacylglycerols and fatty acid methyl esters. Triacylglycerol may be formed via 2-monoacylglycerol
-
-
?
additional information
?
-
-
the enzyme also uses soybean oil, sesame oil, rapeseed oil, camellia oil, olive oil and linseed oil as substrates. 1,3-dicaprylin, 1,3-dipalmitin, 1,2-diolein, 1,3-diolein, 1,2-dilinolein, methylbutyrate, methyllaurate, methylpalmitate, methylpamitoleate, methylsterate, methyllinoleate, methyllinolenate, and methyleicosapentaenoate yield no detectable activity at either 30 or 50°C
-
-
?
additional information
?
-
-
monoacylglycerols containing long-chain unsaturated fatty acids and phosphatidylcholine are preferentially hydrolyzed over triacylglycerols and fatty acid methyl esters. Triacylglycerol may be formed via 2-monoacylglycerol
-
-
?
additional information
?
-
-
the enzyme also uses soybean oil, sesame oil, rapeseed oil, camellia oil, olive oil and linseed oil as substrates. 1,3-dicaprylin, 1,3-dipalmitin, 1,2-diolein, 1,3-diolein, 1,2-dilinolein, methylbutyrate, methyllaurate, methylpalmitate, methylpamitoleate, methylsterate, methyllinoleate, methyllinolenate, and methyleicosapentaenoate yield no detectable activity at either 30 or 50°C
-
-
?
additional information
?
-
-
catalyzes the last step in the hydrolysis of stored triglycerides in the adipocytes
-
-
?
additional information
?
-
-
inhibition of the enzyme potentiates the activation of 2-arachidonoylglycerol production by ATP
-
-
?
additional information
?
-
-
enzyme activity with 1-, 2-, and 3- monoacylglycerols as substrates is similar
-
-
?
additional information
?
-
-
enzyme activity with 1-, 2-, and 3-monoacylglycerols as substrates is similar
-
-
?
additional information
?
-
-
tissue-specific developmental and nutritional regulation of the enzyme, post-transcriptional regulation of expression occurs in the intestine, while transcriptional regulation is the primary mechanism for hepatic MGL expression, overview
-
-
?
additional information
?
-
-
tissue-specific developmental and nutritional regulation of the enzyme, post-transcriptional regulation of expression occurs in the intestine, while transcriptional regulation is the primary mechanism for hepatic MGL expression, overview
-
-
?
additional information
?
-
-
Rv0183, as exported enzyme, may be involved in the degradation of the host cell lipids
-
-
?
additional information
?
-
-
substrate specificity, the enzyme hydrolyses monoacylglycerol substrates, both long chain di- and triacylglycerols, although the turnover is lower than with monoacylglycerol, overview, no activity of the recombinant enzyme with lysophospholipid substrates, recombinant Rv0183 hydrolyses synthetic vinyl esters with various acyl chain lengths, chain length dependence, overview
-
-
?
additional information
?
-
docking studies with the substrate 1-oleoyl-glycerol in the form of the tetrahedral reaction intermediate. In the best-docking mode, the polar glycerol moiety of the substrate is in direct interaction with catalytically important residues Ser110, His256, Glu257, Met111 and Leu39 from the core region and Tyr181 situated within helix 3 of the cap. No positional preference for sn-1(3) or 2-MGs has been reported for any MGL
-
-
?
additional information
?
-
-
docking studies with the substrate 1-oleoyl-glycerol in the form of the tetrahedral reaction intermediate. In the best-docking mode, the polar glycerol moiety of the substrate is in direct interaction with catalytically important residues Ser110, His256, Glu257, Met111 and Leu39 from the core region and Tyr181 situated within helix 3 of the cap. No positional preference for sn-1(3) or 2-MGs has been reported for any MGL
-
-
?
additional information
?
-
docking studies with the substrate 1-oleoyl-glycerol in the form of the tetrahedral reaction intermediate. In the best-docking mode, the polar glycerol moiety of the substrate is in direct interaction with catalytically important residues Ser110, His256, Glu257, Met111 and Leu39 from the core region and Tyr181 situated within helix 3 of the cap. No positional preference for sn-1(3) or 2-MGs has been reported for any MGL
-
-
?
additional information
?
-
-
Rv0183, as exported enzyme, may be involved in the degradation of the host cell lipids
-
-
?
additional information
?
-
-
substrate specificity, the enzyme hydrolyses monoacylglycerol substrates, both long chain di- and triacylglycerols, although the turnover is lower than with monoacylglycerol, overview, no activity of the recombinant enzyme with lysophospholipid substrates, recombinant Rv0183 hydrolyses synthetic vinyl esters with various acyl chain lengths, chain length dependence, overview
-
-
?
additional information
?
-
docking studies with the substrate 1-oleoyl-glycerol in the form of the tetrahedral reaction intermediate. In the best-docking mode, the polar glycerol moiety of the substrate is in direct interaction with catalytically important residues Ser110, His256, Glu257, Met111 and Leu39 from the core region and Tyr181 situated within helix 3 of the cap. No positional preference for sn-1(3) or 2-MGs has been reported for any MGL
-
-
?
additional information
?
-
-
no activity with triacetin, tributyrin, trioctanoin, triolein, dioctanoin, dimyristin, monooctanoin, diolein, and Tween 80
-
-
?
additional information
?
-
-
no activity with triacetin, tributyrin, trioctanoin, triolein, dioctanoin, dimyristin, monooctanoin, diolein, and Tween 80
-
-
?
additional information
?
-
-
enzyme also catalyzes monoglyceride synthesis in a solvent-free two-phase system, in which fatty acid droplets are dispersed in the glycerol phase with a low water content, enzyme does not hydrolyze di- and triglycerides
-
?
additional information
?
-
-
enzyme also catalyzes monoglyceride synthesis in a solvent-free two-phase system, in which fatty acid droplets are dispersed in the glycerol phase with a low water content, enzyme does not hydrolyze di- and triglycerides
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
no activity against long-chain diacylglycerols and triacylglycerols, cholesterol ester, or lysophosphatidylcholine
-
-
?
additional information
?
-
-
substrate specificity, overview
-
-
?
additional information
?
-
enzyme does not hydrolyze palmitoylethanolamine, enzyme preferentially hydrolyzes 2-monoglycerides
-
?
additional information
?
-
-
enzyme exhibits both phosphatidic acid-preferring phospholipase A2 and monoacylglycerol lipase activities with a modest specificity towards unsaturated acyl chains, veryl low di- and triaclyglycerol lipase activity
-
?
additional information
?
-
-
monoacylglycerol lipase is required in the final hydrolysis of 2-monoacylglycerols produced by hormone-sensitive lipase
-
-
?
additional information
?
-
-
the enzyme is involved in prostaglandin metabolism in brain particulate fractions
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(2R,9Z)-octadec-9-ene-1,2-diamine dihydrochloride
-
inhibits by 42.2%
(2S)-6-[4-(hexyloxy)phenyl]hexane-1,2-diamine
-
exhibits weak inhibitory activity (25.9%)
(2S,9Z)-octadec-9-ene-1,2-diamine
-
selectively inhibits MGL by 49.9%. The presence of a long monounsaturated chain corresponding to oleic acid is a key requirement for the selective inhibition of MGL
(3R)-1-(3,4-dimethylphenyl)-5-oxo-N-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]pyrrolidine-3-carboxamide
51.85% residual activity at 0.1 mM
(3R)-N-(3,5-dimethylphenyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide
18.61% residual activity at 0.1 mM
(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
-
16% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
(3S)-N-(1,3-benzodioxol-4-ylmethyl)-1-[4-[(2-chlorobenzyl)oxy]phenyl]-5-oxopyrrolidine-3-carboxamide
51.09% residual activity at 0.1 mM
(4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)-methanone
-
(4-amidinophenyl) methanesulfonyl fluoride
-
i.e. APMSF, inhibits at 0.5 mM
(4-[4-chlorobenzoyl]piperidin-1-yl)(4-methoxyphenyl)-methanone
-
(5E)-5-(3-methylbutylidene)-2-thioxo-1,3-thiazolidin-4-one
-
weak inhibitory effect
(5Z,8Z,11Z,14Z)-eicosantetraenoic acid 3-thienyl methyl ester
-
i.e. CAY-10402, 14% inhibition at 0.1 mM
(R)-2-aminohexadecanol
-
inhibits by 30%
(S)-2-aminohexadecanol
-
inhibits by 31.5%
1,2-diaminohexadecane
-
inhibits by 30.3%
1-(20-cyano-16,16-dimethyl-eicosa-5,8,11,14-tetraenoyl)glycerol
-
i.e. O-223
1-(20-hydroxy-16,16-dimethyl-eicosa-5,8,11,14-tetraenoyl)glycerol
-
i.e. O-224
1-(3-phenylpropanoyl)-(3R,4R)-3-[1(R)-(3-phenylpropanoyloxy)-ethyl]-4-(acetoxy)-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(3-phenylpropanoyl)-(3R,4R)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-4-(acetoxy)-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(3-phenylpropanoyl)-(3R,4R)-3-[1(R)-(biphenylacetyloxy)-ethyl]-4-(acetoxy)-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0; 66% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(3-phenylpropanoyl)-(3S)-3-[1(R)-(3-phenylpropanoyloxy)-ethyl]-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(3-phenylpropanoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(3-phenylpropanoyl)-(3S)-3-[1(R)-(5-phenylpentanoyloxy)-ethyl]-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(3-phenylpropanoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
-
31% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(4-phenylbutanoyl)-(3R,4R)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-4-(acetoxy)-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(4-phenylbutanoyl)-(3R,4R)-3-[1(R)-hydroxyethyl]-4-(acetoxy)-azetidin-2-one
-
61% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(4-phenylbutanoyl)-(3S)-3-[1(R)-(3-phenylpropanoyloxy)-ethyl]-azetidin-2-one
-
54% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(4-phenylbutanoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
-
100% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(4-phenylbutanoyl)-(3S)-3-[1(R)-(5-phenylpentanoyloxy)-ethyl]-azetidin-2-one
-
59% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(5-phenylpentanoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
-
39% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(5-phenylpentanoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
-
25% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(hexa-5-enoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
-
85% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(hexa-5-enoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
-
67% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3R,4R)-3-[1(R)-(pent-4-enoyloxy)-ethyl]-4-(acetoxy)-azetidin-2-one
-
99% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3R,4R)-3-[1(R)-hydroxyethyl]-4-(acetoxy)-azetidin-2-one
-
16% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0; 8% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
-
89% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
-
91% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3S)-3-[1(R)-(hexa-5-enoyloxy)-ethyl]-azetidin-2-one
-
8% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3S)-3-[1(R)-(pent-4-enoyloxy)-ethyl]-azetidin-2-one
-
99% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-(pent-4-enoyl)-(3S)-3-[1(R)-hydroxyethyl]-azetidin-2-one
-
89% inhibition, with 0.1 mM of inhibitor, at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
1-arachidin
-
11% inhibition of the membraneous enzyme at 0.1 mM, 19% inhibition of the cytosolic enzyme at 0.1 mM
1-methylethyl dodecylphosphonofluoridoate
-
highly potent inhibitor
1-myristin
-
IC50 value for the membraneous and the cytosolic enzyme is 0.032 mM, complete inhibition is possible
1-nor-arachidonoyl-3-(2'3-dihydroxypropyl) urea
-
i.e. O-1502, 39% inhibition at 0.1 mM
1-palmitin
-
44% inhibition of the membraneous enzyme at 0.1 mM, 38% inhibition of the cytosolic enzyme at 0.1 mM
12-deacetylsplendidin C
poor inhibition
15-deoxy-DELTA12,14-prostaglandin J2
1H-benzotriazol-1-yl(4-benzylpiperazin-1-yl)methanone
-
1H-benzotriazol-1-yl[4-(4-bromobenzyl)piperazin-1-yl]methanone
-
1H-benzotriazol-1-yl[4-(4-nitrobenzyl)piperazin-1-yl]methanone
-
1H-benzotriazol-1-yl[4-(naphthalen-2-ylmethyl)piperazin-1-yl]methanone
-
1H-benzotriazol-1-yl[4-[(2E)-3-phenylprop-2-en-1-yl]piperazin-1-yl]methanone
-
2,3-dihydroxypropyl (11Z)-icos-11-enoate
-
i.e. O-4066, IC50 value for the membraneous enzyme is 0.026 mM, for the cytosolic enzyme 0.019 mM, complete inhibition of the membraneous enzyme is possible, maximal inhibition of the cytosolic enzyme of 79%
2,3-dihydroxypropyl (11Z,14Z)-icosa-11,14-dienoate
-
i.e. O-3907, IC50 value for the membraneous enzyme is 0.016 mM, for the cytosolic enzyme 0.0051 mM, complete inhibition is possible
2,3-dihydroxypropyl (4Z,7Z,10Z,13Z)-17-ethylcycloheptadeca-4,7,10,13-tetraene-1-carboxylate
-
i.e. O-1428, IC50 value for the membraneous enzyme is 0.071 mM, for the cytosolic enzyme 0.015 mM, complete inhibition is possible
2,3-dihydroxypropyl (5Z)-icos-5-enoate
-
i.e. 3908, IC50 value for the membraneous enzyme is 0.056 mM, for the cytosolic enzyme 0.021 mM, complete inhibition of the membraneous enzyme is possible, maximal inhibition of the cytosolic enzyme of 65%
2,3-dihydroxypropyl (5Z,8Z,11Z)-2-ethylcycloheptadeca-5,8,11-triene-1-carboxylate
-
i.e. O-3973, IC50 value for the membraneous enzyme is 0.0083 mM, for the cytosolic enzyme 0.0042 mM, complete inhibition is possible
2,3-dihydroxypropyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
-
i.e. O-3832, IC50 value for the membraneous enzyme is 0.017 mM, for the cytosolic enzyme 0.0082 mM, complete inhibition is possible
2,3-dihydroxypropyl (6Z,9Z,12Z,15Z)-cyclohenicosa-6,9,12,15-tetraene-1-carboxylate
-
IC50 value for the membraneous enzyme is 0.0051 mM, for the cytosolic enzyme 0.0058 mM, complete inhibition is possible
2,3-dihydroxypropyl (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoate
-
IC50 value for the membraneous enzyme is 0.011 mM, for the cytosolic enzyme 0.0045 mM, complete inhibition is possible
2,3-dihydroxypropyl (8Z,11Z,14Z)-icosa-8,11,14-trienoate
-
i.e. 3846, IC50 value for the membraneous enzyme is 0.073 mM, for the cytosolic enzyme 0.0075 mM, complete inhibition is possible
2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-2-O-acetyl-4-O-(4-coumaroyl)-beta-D-glucopyranoside
-
2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-2-O-acetyl-4-O-beta-D-glucopyranoside
the inhibitor is selective for hMAGL over hLDH, modeling of the binding mode in the MAGL active site. The sugar moiety lies in the wide lipophilic cavity of the protein forming lipophilic interactions with L148, L213, L241, and V183, whereas the 4-hydroxyphenyl-ethyl ring lies into the small pocket of the binding site and forms lipophilic interactions with residues Y194 and V270. A high number of H-bonds stabilizes the binding disposition of the compound
2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-beta-D-glucopyranoside
-
2-(7-methoxy-2-oxo-2H-chromen-3-yl)-N-(2-methoxyphenyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-6-carboxamide
-
2-(nonylsulfanyl)-4H-1,3,2-benzodioxaphosphinine 2-oxide
-
-
2-dehydroxysalvileucanthsin A
poor inhibition
2-mercaptoethanol
-
50% residual activity at 1 mM
2-methyl-4-isothiazolin-3-one
-
-
2-octyl-4-isothiazolin-3-one
-
octhilinone, inhibits purified recombinant MGL through a partially reversible mechanism that involves a specific interaction with cysteine 208
2-octyl-benzo[d]isothiazol-3-one
-
-
2-oleoyl-4-isothiazolin-3-one
-
-
3-methoxy-N-phenyl-1,2,4-thiadiazol-5-amine
-
weak inhibitory effect
3-[(4S)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]-2,5-dioxoimidazolidin-4-yl]-N-[(1R,2R)-2-methylcyclohexyl]propanamide
57.6% residual activity at 0.1 mM
4-chlormercurybenzoate
IC50 value is 0.072 mM
4-chloromercuribenzoic acid
-
-
4-cyanophenyl ethyl dodecylphosphonate
-
highly potent inhibitor
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
4-nitrophenyl dodecyl(1-methylethyl)phosphinate
-
-
5-[(biphenyl-4-yl)methyl]-N,N-dimethyl-2H-tetrazole-2-carboxamide
AM6701, conforms to the L shape of the binding site, contacts with the binding site are similar to those seen with the 2-arachidonoylglycerol docking pose. The close contacts with A164 and K165 are lost as the subpocket is not occupied. Instead the biphenyl moiety, which extends further up the binding pocket, makes additional contacts with A156, T157 and K160, thus AM6701 is a non-selective inhibitor
6-methyl-2-p-tolylamino-benzo[d] [1,3]oxazin-4-one
6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one
-
URB754, inhibition of brain MAGL expressed in HeLa cells, no inhibition of membrane-bound MAGL. Is not selective for MAGL
alpha-methyl-1-arachidonoyl glycerol
-
compound O-1428, inhibits both cytosolic and membrane-bound MAGL
alpha-methyl-1-arachidonoylglycerol
-
IC50 value is 0.011 mM
AM6580
-
irreversible inhibitor, i.e. [4-(9H-fluoren-9-yl)-piperazin-1-yl][1,2,3]triazolo[4,5-b]pyridin-1-ylmethanone
arachidonic acid
-
IC50 value is 0.078 mM
arachidonoyl glycine
-
42% inhibition at 0.1 mM
arachidonoyl serinol
-
IC50 value is 0.073 mM
arachidonoyl trifluoromethylketone
arachidonoyltrifluoromethyl ketone
arachidonoyltrifluoromethylketone
-
-
arachidonyl trifluoromethylketone
-
-
ATP
-
slightly inhibiting
benzol
-
IC50 is 0.012 mM
benzyl [4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl]carbamate
5.12% residual activity at 0.1 mM
benzylphenylcarbamate
-
-
biphenyl-3-yl-carbamic acid cyclohexyl ester
-
i.e. URB602
celastrol
-
inhibits MGL activity, albeit less potently than pristimerin
Co2+
-
47% residual activity at 1 mM
Cu2+
-
35% residual activity at 1 mM
decyl benzodioxaphosphorin oxide
-
IC50 is 0.80 nM
deoxycholate
-
17% inhibition at 5 mM
diazoxon
-
IC50 is 0.014 mM
dichlorvos
-
IC50 is 0.013 mM
diethyl 3,5,6-trichloropyridin-2-yl phosphate
-
-
diethyl 4-nitrophenyl phosphate
-
-
Diethyl p-nitrophenyl phosphate
diethyldicarbonate
-
20% residual activity at 1 mM
dihydrocelastrol
-
inhibits MGL activity, albeit less potently than pristimerin
dihydrocelastryl diacetate
-
inhibits MGL activity, albeit less potently than pristimerin
diisopropyl fluorophosphate
diisopropylfluorophosphate
-
75% residual activity at 1 mM
dodecane-1-sulfonyl fluoride
-
-
dodecyl benzodioxaphosphorin oxide
-
IC50 is 0.83 nM
dodecyl sulfonyl fluoride
-
IC50 is 200 nM
EDTA
-
50% residual activity at 1 mM
ethyl 3,5,6-trichloropyridin-2-yl dodecylphosphonate
-
-
ethyl octylphosphonofluoridate
euphol
-
inhibits MGL activity with high potency. Blocks MGL activity through a reversible and noncompetitive mechanism, which is apparently identical to that of pristimerin
Fe3+
-
35% residual activity at 1 mM
heptyl benzodioxaphosphorin oxide
-
IC50 is 45 nM
hexadecylsufonyl fluoride
Hg2+
-
30% residual activity at 1 mM
isopropyl dodecylfluorophosphate
-
i.e. IDFP, n-C12H25P(O)(OCH3)F, IC50 is 0.76 nM
isopropyl dodecylfluorophosphonate
-
is not selective for MAGL
isopropyldodecylfluorophosphonate
-
-
jewenol A
reversible inhibitor, catalytic site binding structure, overview
JJKK-048
-
i.e. 4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone
LY2183240
is less potent than JZL184
Maleimide
IC50 value is 0.070 mM
methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14- tetraenylphosphonofluoridate
-
completely inhibits 4-nitophenyl acetate hydrolysis by pure human MGL at 0.1 mM
methyl arachidonyl fluorophosphonate
methyl icosylphosphonofluoridoate
-
-
methyl octylphosphonofluoridate
methylarachidonoylfluorophosphonate
-
-
MJN110
inhibits glucose-stimulated insulin secretion and depolarization-induced insulin secretion in INS-1 (832/13) cells
Mn2+
-
58% residual activity at 1 mM
N-(1-pyrenyl)-maleimide
IC50 value is 0.068 mM
N-(2-hydroxyethyl)-2-oxopentadecanamide
-
exhibits weak inhibitory activity (27.5%) and no selectivity towards MGL
N-(4-hydroxy-2-methylphenyl)arachidonylamide
-
i.e. VDM11, an anandamide uptake inhibitor, substrate of fatty acid amide hydrolase, EC 3.5.1.4, IC50 is 0.021 mM
N-(4-hydroxyphenyl)arachidonylamide
-
i.e. AM404, an anandamide uptake inhibitor, substrate of fatty acid amide hydrolase, EC 3.5.1.4, IC50 is 0.020 mM
N-benzoylthiocarbamic cyclohexylethyl ester
-
-
N-cyclohexylmaleimide
IC50 value is 0.051 mM
N-hydroxymaleimide
IC50 value is 0.413 mM
N-n-heptyl benzodioxaphosphorin oxide
-
IC50 is 150 nM
N-Phenylmaleimide
IC50 value is 0.044 mM
N-propylmaleimide
IC50 value is 0.053 mM
N-[3-(4-fluorophenyl)-6-oxopyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazin-7(6H)-yl]-2-(naphthalen-2-yloxy)acetamide
72.3% residual activity at 0.1 mM
N-[4-(1,3-benzothiazol-2-yl)phenyl]-2-(1H-benzotriazol-1-yl)acetamide
14.28% residual activity at 0.1 mM
noladin ether
-
IC50 value is 0.036 mM
O-n-octyl benzodioxaphosphorin oxide
-
IC50 is 150 nM
octane-1-sulfonyl fluoride
-
-
octyl sulfonyl fluoride
-
IC50 is 140 nM
p-bromophenacyl bromide
-
partial inhibition
p-chloromercuribenzoic acid
-
45% residual activity at 1 mM
paraoxon
-
IC50 is 0.0023 mM
phenylmethylsulfonyl fluoride
pinoresinol 4-O-beta-D-glucopyranoside
-
pristimerol
-
inhibits MGL activity, albeit less potently than pristimerin
pseudorosmaricin
poor inhibition
S-heptyl benzodioxaphosphorin oxide
-
IC50 is 2.9 nM
S-nonyl benzodioxaphosphorin oxide
-
IC50 is 0.31 nM
S-nonylbenzodioxaphosphorin oxide
-
is not selective for MAGL
S-pentyl benzodioxaphosphorin oxide
-
IC50 is 3.1 nM
stearyl benzodioxaphosphorin oxide
-
IC50 is 51 nM
Triton X-100
-
10% inhibition at 0.25%
URB-602
-
a specific MGL inhibitor
Zn2+
-
27% residual activity at 1 mM
[1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester
-
URB602, noncompetetive selective inhibitor
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
[4-[bis(1,3-benzodioxol-5-yl)methyl]-1-piperidinyl](1H-1,2,4-triazol-1-yl)methanone
a highly potent selective inhibitor
1-arachidonoylglycerol
-
IC50 value for the membraneous enzyme is 0.0095 mM, for the cytosolic enzyme 0.0071 mM, complete inhibition is possible
1-arachidonoylglycerol
-
inhibits the hydrolysis of cytosolic 2-oleoylglycerol, IC50 value is 0.017 mM, the affinity for the enzyme is highest with an arachidonyl side chain and decreases to fatty acids of shorter chain length
15-deoxy-DELTA12,14-prostaglandin J2
-
-
15-deoxy-DELTA12,14-prostaglandin J2
-
-
2-arachidonoylglycerol
-
-
2-arachidonoylglycerol
-
inhibits the hydrolysis of cytosolic 2-oleoylglycerol, IC50 value is 0.013 mM, the affinity for the enzyme is highest with an arachidonyl side chain and decreases to fatty acids of shorter chain length
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
-
JZL184
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
-
JZL184
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
-
JZL184
6-methyl-2-p-tolylamino-benzo[d] [1,3]oxazin-4-one
-
i.e. URB754
6-methyl-2-p-tolylamino-benzo[d] [1,3]oxazin-4-one
-
i.e. URB754
6-methyl-2-p-tolylamino-benzo[d] [1,3]oxazin-4-one
-
i.e. URB754
AM404
-
-
AM6701
-
5-((biphenyl-4-yl)methyl)-N,N-dimethyl-2H-tetrazole-2-carboxamide
AM6701
-
MGL inhibition by AM6701 involves a covalent interaction resulting in the enzyme's rapid, selective carbamoylation at its catalytic serine nucleophile (Ser122)
AM6701
-
slowly reversible inhibition, i.e. 5-((biphenyl-4-yl)methyl)-N,N-dimethyl-2H-tetra-zole-2-carboxamide
arachidonoyl trifluoromethylketone
-
causes a gradual suppression of cannabinoid-sensitive IPSCs in cultured hippocampal neurons, the suppression is reversed by blocking CB1 receptors and is attenuated by inhibiting 2-AG synthesis, overview
arachidonoyl trifluoromethylketone
-
50% inhibition at 0.066 mM
arachidonoyl trifluoromethylketone
-
50% inhibition at 0.0025 mM
arachidonoyl trifluoromethylketone
50% inhibition at 0.0025 mM
arachidonoyl trifluoromethylketone
-
the affinity for the enzyme is highest with an arachidonyl side chain and decreases to fatty acids of shorter chain length
arachidonoyl trifluoromethylketone
-
causes a gradual suppression of cannabinoid-sensitive IPSCs in cultured hippocampal neurons, the suppression is reversed by blocking CB1 receptors and is attenuated by inhibiting 2-AG synthesis, overview
arachidonoyltrifluoromethyl ketone
-
i.e. ATFMK
arachidonoyltrifluoromethyl ketone
-
i.e. ATFMK, inhibition is reversible by AM281
arachidonoyltrifluoromethyl ketone
-
i.e. ATFMK, inhibition is reversible by AM281
CAY 10415
-
-
CAY 10514
-
-
chlorpyrifos oxon
-
IC50 is 34 nM
chlorpyrifos oxon
-
is not selective for MAGL
ciglitazone
-
-
CP55,940
-
-
Diethyl p-nitrophenyl phosphate
-
-
Diethyl p-nitrophenyl phosphate
-
-
diisopropyl fluorophosphate
-
-
diisopropyl fluorophosphate
-
i.e. DFP, n-C8H17P(O)(OCH3)F, IC50 is 0.045 mM
diisopropyl fluorophosphate
-
-
Disulfiram
-
i.e. tetraethylthiuram disulfide, a compound used to treat alcoholism, inhibition likely through an interaction with cysteine residues Cys208 and/or Cys242, the inhibition is reversible by DTT
ethyl octylphosphonofluoridate
-
i.e. EOFP, n-C8H17P(O)(OC2H5)F, IC50 is 3.0 nM
ethyl octylphosphonofluoridate
-
is not selective for MAGL
hexadecylsufonyl fluoride
-
50% inhibition at 0.000241 mM
hexadecylsufonyl fluoride
-
50% inhibition at 0.0062 mM
hexadecylsufonyl fluoride
50% inhibition at 0.0062 mM
HgCl2
IC50 value is 0.042 mM
JZL184
-
JZL184
is more potent than LY2183240. The p-nitrophenyl group fits better in the MAGL cavity than the corresponding substituent of LY2183240
JZL184
MGL-selective inhibitor, represents a ligand with increased steric bulk over AM6701 and 2-arachidonoylglycerol. Extra bulk fills the binding site more completely and one 1,3-benzodioxole moiety makes additional contacts with the lid region of MGL. There is also a weak hydrogen bond from N195 to the p-nitro substituent
JZL184
-
time-dependent inhibitor
JZL184
-
irreversible inhibitor
JZL184
-
i.e. 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate
JZL184
-
selective inhibitor
JZL184
-
time-dependent inhibitor
JZL184
-
irreversible inhibitor
JZL184
significantly decreases lipolysis and increases both mono- and diacyglycerol species in INS-1 cells. Analysis of the kinetics of glucose-stimulated insulin secretion (GSIS) shows that inhibition is greater during the sustained phase of secretion. JZL184 does not significantly affect basal insulin secretion at any concentration tested. Kinetics, overview
meloxicam
-
-
methyl arachidonyl fluorophosphonate
-
i.e. MAFP
methyl arachidonyl fluorophosphonate
-
MAFP
methyl arachidonyl fluorophosphonate
irreversible active-site inhibitor of monoglyceride lipase
methyl arachidonyl fluorophosphonate
-
methyl arachidonyl fluorophosphonate
-
-
methyl arachidonyl fluorophosphonate
-
i.e. MAFP, n-C20H33P(O)(OCH3)F
methyl arachidonyl fluorophosphonate
-
causes a gradual suppression of cannabinoid-sensitive IPSCs in cultured hippocampal neurons, the suppression is reversed by blocking CB1 receptors and is attenuated by inhibiting 2-AG synthesis, overview; i.e. MAFP
methyl arachidonyl fluorophosphonate
-
MAFP
methyl arachidonyl fluorophosphonate
-
50% inhibition at 0.0000022 mM
methyl arachidonyl fluorophosphonate
-
50% inhibition at 0.0008 mM
methyl arachidonyl fluorophosphonate
-
i.e. MAFP, inhibits at 0.05 mM
methyl arachidonyl fluorophosphonate
50% inhibition at 0.0008 mM
methyl arachidonyl fluorophosphonate
-
causes a gradual suppression of cannabinoid-sensitive IPSCs in cultured hippocampal neurons, the suppression is reversed by blocking CB1 receptors and is attenuated by inhibiting 2-AG synthesis, overview; i.e. MAFP
methyl arachidonyl fluorophosphonate
-
MAFP
methyl octylphosphonofluoridate
-
i.e. MOFP, n-C8H17P(O)(OCH3)F, IC50 is 3.0 nM
methyl octylphosphonofluoridate
-
is not selective for MAGL
N-arachidonoyl dopamine
-
-
N-arachidonoyl dopamine
-
-
N-arachidonoylmaleimide
-
irreversible inhibition
N-arachidonoylmaleimide
-
-
N-arachidonoylmaleimide
-
inhibits MGL through partial enzyme alkylation at Cys208 and/or Cys242 (Cys242 being favored)
N-arachidonoylmaleimide
-
-
N-arachidonoylmaleimide
IC50 value is 0.00014 mM
N-arachidonyl maleimide
-
potent irreversible inhibitor of MAGL, inhibits in a dose-dependent manner
N-arachidonyl maleimide
-
protects 2-arachidonoylglycerol from metabolic degradation
N-arachidonylmaleimide
-
-
N-arachidonylmaleimide
Cys201 is the crucial residue in MAGL inhibition by N-arachidonylmaleimide
N-arachidonylmaleimide
-
inhibitory effect is attributed to the ability of this compound to react with C242 and form a Michael addition product
N-arachidonylmaleimide
-
inhibits membrane-bound MAGL selectively
N-ethylmaleimide
-
-
NaCl
-
1 M, 63% loss of activity
NaF
-
-
NEM
IC50 value is 0.053 mM
phenylmethylsulfonyl fluoride
PMSF is able to produce an irreversible MAGL-PMSF adduct and hydrofluoric acid (HF), by specifically binding to the hydroxyl group of the serine residue in the active site of the serine protease, thereby inhibiting its enzymatic activity; PMSF is able to produce an irreversible MAGL-PMSF adduct and hydrofluoric acid (HF), by specifically binding to the hydroxyl group of the serine residue in the active site of the serine protease, thereby inhibiting its enzymatic activity
phenylmethylsulfonyl fluoride
-
phenylmethylsulfonyl fluoride
-
inhibits MGL only at very high concentrations
phenylmethylsulfonyl fluoride
PMSF is able to produce an irreversible MAGL-PMSF adduct and hydrofluoric acid (HF), by specifically binding to the hydroxyl group of the serine residue in the active site of the serine protease, thereby inhibiting its enzymatic activity
phenylmethylsulfonyl fluoride
-
70% residual activity at 1 mM
phenylmethylsulfonyl fluoride
-
50% inhibition at 0.155 mM
PMSF
-
-
pristimerin
-
-
pristimerin
-
inhibits MGL activity with high potency. Addition to purified MGL produces an almost immediate blockade of MGL activity. Inhibits MGL through a mechanism that is rapid, reversible, and noncompetitive
rosiglitazone
-
-
tetrahydrolipstatin
-
-
tetrahydrolipstatin
-
inactivation
troglitazone
-
-
URB602
-
specific inhibitor of MAGL, inhibits in a dose-dependent manner
URB602
-
reversible inhibitor
URB602
inhibits glucose-stimulated insulin secretion and depolarization-induced insulin secretion in INS-1 (832/13) cells
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
-
CAY10499
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
-
CAY10499
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
-
CAY10499
additional information
-
immunodepletion of the enzyme leads to 50% reduced activity
-
additional information
-
no inhibition by URB754
-
additional information
-
inhibitor screening, molecular docking and modeling, no inhibition of MGL by fatty acid amide hydrolase inhibitors, overview
-
additional information
-
not inhibited by CAY10433, WWL70, and URB602
-
additional information
-
URB754 does not inhibit MAGL activity at concentrations up to 0.100 mM. Assay buffer alone or heat-denatured MAGL protein has no significant activity against 7-hydroxycoumarinyl-arachidonate
-
additional information
-
1-(4-phenylbutanoyl)-(3S)-3-[1(R)-hydroxyethyl]-azetidin-2-one, 1-(5-phenylpentanoyl)-(3S)-3-[1(R)-hydroxyethyl]-azetidin-2-one, 1-(hexa-5-enoyl)-(3S)-3-[1(R)-hydroxyethyl]-azetidin-2-one and 1-(4-phenylbutanoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one do not inhibit
-
additional information
diterpenes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL), NMR structure analysis, molecular docking into the catalytic site of the enzyme, overview. No effect by DTT at 0.1 mM and by galloflavin
-
additional information
structure-based MGL inhibitor design
-
additional information
-
structure-based MGL inhibitor design
-
additional information
phenylethanoid glycosides isolated from the n-butanol extract of Cistanche phelypaea aerial parts (collected in March 2012 in the southwest of Algeria) show activity as inhibitors of monoacylglycerol lipase, structure determinations by spectroscopic analyses, including 1D and 2D NMR, and HRESIMS experiments, docking study, overview. No inhibition by galloflavin, apigenin 7-O-beta-D-glucuronopyranoside, and 2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-2-O-acetyl-4-O-(4-coumaroyl)-beta-D-glucopyranoside
-
additional information
-
no inhibition by PMSF and palmityl trifluoromethyl ketone
-
additional information
-
analysis of structure-function relationships; analysis of structure-function relationships, organophosphorus-induced in vivo inhibition, overview
-
additional information
-
inhibitors of other endocannabinoid hydrolyzing enzymes, fatty acid amide hydrolase and cyclooxygenase-2, have no effect on the 2-AG-induced IPSC suppression
-
additional information
-
inactivation by serine esterase inhibitors
-
additional information
Mycobacterium tuberculosis MGL cannot be inhibited with JZL-184, a known inhibitor of human MGL. Differences in the binding pocket of mtbMGL compared to human MGL impair JZL-184 inhibition, overview. The human enzyme has an amphipathic cap helix 1 whereas cap helix1 of mtbMGL is mostly hydrophobic. Structure-based analysis for potential inhibitors for mtbMGL. JZL-184 docking study, overview
-
additional information
-
Mycobacterium tuberculosis MGL cannot be inhibited with JZL-184, a known inhibitor of human MGL. Differences in the binding pocket of mtbMGL compared to human MGL impair JZL-184 inhibition, overview. The human enzyme has an amphipathic cap helix 1 whereas cap helix1 of mtbMGL is mostly hydrophobic. Structure-based analysis for potential inhibitors for mtbMGL. JZL-184 docking study, overview
-
additional information
-
inhibitory potency of different 1-arachidonic acid analogues, the chain length of the fatty acid is important for affinity and inhibition, while methylations of the fatty acids do not influence the inhibitory potency, overview
-
additional information
-
no inhibition by URB597, bovine serum albumin decreases the inhibitory effect of arachidonoyl-based compounds, e.g. VDM11
-
additional information
inhibition by bulky maleimides derivatives is due to steric hindrance of substrate binding after alkylation of cysteines 242 and/or 208, no inhibition by succimide and N-arachidonylsuccimide
-
additional information
-
immunodepletion of the recombinant enzyme leads to 50% reduced activity
-
additional information
-
inhibitor screening, overview
-
additional information
-
inhibitors of other endocannabinoid hydrolyzing enzymes, fatty acid amide hydrolase and cyclooxygenase-2, have no effect on the 2-AG-induced IPSC suppression
-
additional information
-
(2S)-6-phenylhexane-1,2-diamine and (2S,9Z)-2-aminooctadec-9-enamide show no inhibition
-
additional information
-
3-methoxy-N-phenyl-1,2,4-thiadiazol-5-amine and 3-propoxy-2-benzofuran-1(3H)-one do not inhibit
-
additional information
-
is not inhibited by 1 mM N-arachidonylsuccinimide
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.1
(3R)-1-(3,4-dimethylphenyl)-5-oxo-N-[(4-oxo-3,4-dihydrophthalazin-1-yl)methyl]pyrrolidine-3-carboxamide
Homo sapiens
IC50 around 0.1 mM, pH and temperature not specified in the publication
0.000039
(3R)-N-(3,5-dimethylphenyl)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]-5-oxopyrrolidine-3-carboxamide
Homo sapiens
pH and temperature not specified in the publication
0.1
(3S)-N-(1,3-benzodioxol-4-ylmethyl)-1-[4-[(2-chlorobenzyl)oxy]phenyl]-5-oxopyrrolidine-3-carboxamide
Homo sapiens
IC50 around 0.1 mM, pH and temperature not specified in the publication
0.0117
(4-(4-chlorobenzoyl)piperidin-1-yl)(4-methoxyphenyl)-methanone
Homo sapiens
pH 7.2, temperature not specified in the publication
0.02
(5E)-5-(3-methylbutylidene)-2-thioxo-1,3-thiazolidin-4-one
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.00851
1-(hexa-5-enoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.0146
1-(hexa-5-enoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.133
1-(pent-4-enoyl)-(3R,4R)-3-[1(R)-(pent-4-enoyloxy)-ethyl]-4-(acetoxy)-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.00406
1-(pent-4-enoyl)-(3S)-3-[1(R)-(4-phenylbutanoyloxy)-ethyl]-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.00184
1-(pent-4-enoyl)-(3S)-3-[1(R)-(biphenylacetyloxy)-ethyl]-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.00472
1-(pent-4-enoyl)-(3S)-3-[1(R)-(hexa-5-enoyloxy)-ethyl]-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.0233
1-(pent-4-enoyl)-(3S)-3-[1(R)-(pent-4-enoyloxy)-ethyl]-azetidin-2-one
Homo sapiens
-
at 37°C for 10 min, in 10 mM Tris-HCl buffer, 1 mM EDTA, 0.1% (w/v) bovine serum albumin, pH 8.0
0.0095 - 0.017
1-arachidonoylglycerol
0.0000008
1-methylethyl dodecylphosphonofluoridoate
Mus musculus
-
-
0.032
1-myristin
Rattus norvegicus
-
IC50 value for the membraneous and the cytosolic enzyme is 0.032 mM, complete inhibition is possible
0.2
12-deacetylsplendidin C
Homo sapiens
above, pH 7.2, temperature not specified in the publication
0.026
2,3-dihydroxypropyl (11Z)-icos-11-enoate
Rattus norvegicus
-
i.e. O-4066, IC50 value for the membraneous enzyme is 0.026 mM, for the cytosolic enzyme 0.019 mM, complete inhibition of the membraneous enzyme is possible, maximal inhibition of the cytosolic enzyme of 79%
0.016
2,3-dihydroxypropyl (11Z,14Z)-icosa-11,14-dienoate
Rattus norvegicus
-
i.e. O-3907, IC50 value for the membraneous enzyme is 0.016 mM, for the cytosolic enzyme 0.0051 mM, complete inhibition is possible
0.071
2,3-dihydroxypropyl (4Z,7Z,10Z,13Z)-17-ethylcycloheptadeca-4,7,10,13-tetraene-1-carboxylate
Rattus norvegicus
-
i.e. O-1428, IC50 value for the membraneous enzyme is 0.071 mM, for the cytosolic enzyme 0.015 mM, complete inhibition is possible
0.056
2,3-dihydroxypropyl (5Z)-icos-5-enoate
Rattus norvegicus
-
i.e. 3908, IC50 value for the membraneous enzyme is 0.056 mM, for the cytosolic enzyme 0.021 mM, complete inhibition of the membraneous enzyme is possible, maximal inhibition of the cytosolic enzyme of 65%
0.0083
2,3-dihydroxypropyl (5Z,8Z,11Z)-2-ethylcycloheptadeca-5,8,11-triene-1-carboxylate
Rattus norvegicus
-
i.e. O-3973, IC50 value for the membraneous enzyme is 0.0083 mM, for the cytosolic enzyme 0.0042 mM, complete inhibition is possible
0.017
2,3-dihydroxypropyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
Rattus norvegicus
-
i.e. O-3832, IC50 value for the membraneous enzyme is 0.017 mM, for the cytosolic enzyme 0.0082 mM, complete inhibition is possible
0.0051
2,3-dihydroxypropyl (6Z,9Z,12Z,15Z)-cyclohenicosa-6,9,12,15-tetraene-1-carboxylate
Rattus norvegicus
-
IC50 value for the membraneous enzyme is 0.0051 mM, for the cytosolic enzyme 0.0058 mM, complete inhibition is possible
0.011
2,3-dihydroxypropyl (7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoate
Rattus norvegicus
-
IC50 value for the membraneous enzyme is 0.011 mM, for the cytosolic enzyme 0.0045 mM, complete inhibition is possible
0.073
2,3-dihydroxypropyl (8Z,11Z,14Z)-icosa-8,11,14-trienoate
Rattus norvegicus
-
i.e. 3846, IC50 value for the membraneous enzyme is 0.073 mM, for the cytosolic enzyme 0.0075 mM, complete inhibition is possible
0.1139
2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-2-O-acetyl-4-O-(4-coumaroyl)-beta-D-glucopyranoside
Homo sapiens
pH 7.4, temperature not specified in the publication
0.088
2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-2-O-acetyl-4-O-beta-D-glucopyranoside
Homo sapiens
pH 7.4, temperature not specified in the publication
0.1174
2-(4-hydroxyphenyl)ethyl alpha-L-rhamnopyranosyl-(1->3)-[alpha-L-rhamnopyranosyl-(1->6)]-beta-D-glucopyranoside
Homo sapiens
pH 7.4, temperature not specified in the publication
0.00000031
2-(nonylsulfanyl)-4H-1,3,2-benzodioxaphosphinine 2-oxide
Mus musculus
-
-
0.013
2-arachidonoylglycerol
Rattus norvegicus
-
inhibits the hydrolysis of cytosolic 2-oleoylglycerol, IC50 value is 0.013 mM, the affinity for the enzyme is highest with an arachidonyl side chain and decreases to fatty acids of shorter chain length
0.2
2-dehydroxysalvileucanthsin A
Homo sapiens
above, pH 7.2, temperature not specified in the publication
1
2-mercaptoethanol
Mortierella alliacea
-
in 50 mM phosphate buffer (pH 7.4), at 30°C
0.000239
2-methyl-4-isothiazolin-3-one
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.000151 - 0.000722
2-octyl-4-isothiazolin-3-one
0.000059
2-octyl-benzo[d]isothiazol-3-one
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.000043
2-oleoyl-4-isothiazolin-3-one
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.028
3-methoxy-N-phenyl-1,2,4-thiadiazol-5-amine
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.1
3-[(4S)-1-[2-(5-fluoro-1H-indol-3-yl)ethyl]-2,5-dioxoimidazolidin-4-yl]-N-[(1R,2R)-2-methylcyclohexyl]propanamide
Homo sapiens
IC50 above 0.1 mM, pH and temperature not specified in the publication
0.072
4-chlormercurybenzoate
Rattus norvegicus
IC50 value is 0.072 mM
0.00000007
4-cyanophenyl ethyl dodecylphosphonate
Mus musculus
-
-
0.00021 - 0.0037
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
0.00000028
4-nitrophenyl dodecyl(1-methylethyl)phosphinate
Mus musculus
-
-
0.0002
6-methyl-2-[(4-methylphenyl)amino]-4H-3,1-benzoxazin-4-one
Rattus norvegicus
-
MAGL expressed in HeLa cells
0.01 - 0.071
alpha-methyl-1-arachidonoyl glycerol
0.011
alpha-methyl-1-arachidonoylglycerol
Rattus norvegicus
-
IC50 value is 0.011 mM
0.0031
AM404
Homo sapiens
-
pH and temperature not specified in the publication
0.0000009 - 0.0000017
AM6701
0.078
arachidonic acid
Rattus norvegicus
-
IC50 value is 0.078 mM
0.073
arachidonoyl serinol
Rattus norvegicus
-
IC50 value is 0.073 mM
0.00184
arachidonoyltrifluoromethylketone
Homo sapiens
-
-
0.012
benzol
Mus musculus
-
IC50 is 0.012 mM
0.000424
benzyl [4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3(2H)-yl)-2-methylphenyl]carbamate
Homo sapiens
pH and temperature not specified in the publication
0.0016
celastrol
Rattus norvegicus
-
purified MGL, at pH 7.5, 37°C
0.000034
chlorpyrifos oxon
0.0049
CP55,940
Homo sapiens
-
pH and temperature not specified in the publication
0.0000008
decyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 0.80 nM
0.014
diazoxon
Mus musculus
-
IC50 is 0.014 mM
0.013
dichlorvos
Mus musculus
-
IC50 is 0.013 mM
0.00001
diethyl 3,5,6-trichloropyridin-2-yl phosphate
Mus musculus
-
-
0.0023
diethyl 4-nitrophenyl phosphate
Mus musculus
-
-
0.015
dihydrocelastrol
Rattus norvegicus
-
purified MGL, at pH 7.5, 37°C
0.015
dihydrocelastryl diacetate
Rattus norvegicus
-
purified MGL, at pH 7.5, 37°C
0.045
diisopropyl fluorophosphate
Mus musculus
-
i.e. DFP, n-C8H17P(O)(OCH3)F, IC50 is 0.045 mM
0.0008
Disulfiram
Homo sapiens
-
-
0.0002
dodecane-1-sulfonyl fluoride
Mus musculus
-
-
0.00000083
dodecyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 0.83 nM
0.0002
dodecyl sulfonyl fluoride
Mus musculus
-
IC50 is 200 nM
1
EDTA
Mortierella alliacea
-
in 50 mM phosphate buffer (pH 7.4), at 30°C
0.00000014
ethyl 3,5,6-trichloropyridin-2-yl dodecylphosphonate
Mus musculus
-
-
0.000003
ethyl octylphosphonofluoridate
0.000315 - 0.000882
euphol
0.000045
heptyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 45 nM
0.042
HgCl2
Rattus norvegicus
IC50 value is 0.042 mM
0.00000076
isopropyl dodecylfluorophosphate
Mus musculus
-
i.e. IDFP, n-C12H25P(O)(OCH3)F, IC50 is 0.76 nM
0.00000076
isopropyl dodecylfluorophosphonate
Rattus norvegicus
-
cytosolic MAGL
0.0468
jewenol A
Homo sapiens
pH 7.2, temperature not specified in the publication
0.0002177
JZL184
Homo sapiens
pH 7.4, 22°C
0.07
Maleimide
Rattus norvegicus
IC50 value is 0.070 mM
0.000076
methyl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraen-1-ylphosphonofluoridate
Homo sapiens
-
-
0.0000054 - 0.00016
methyl arachidonyl fluorophosphonate
0.000002
methyl icosylphosphonofluoridoate
Mus musculus
-
-
0.000003
methyl octylphosphonofluoridate
0.068
N-(1-pyrenyl)-maleimide
Rattus norvegicus
IC50 value is 0.068 mM
0.021
N-(4-hydroxy-2-methylphenyl)arachidonylamide
Rattus norvegicus
-
i.e. VDM11, an anandamide uptake inhibitor, substrate of fatty acid amide hydrolase, EC 3.5.1.4, IC50 is 0.021 mM
0.02
N-(4-hydroxyphenyl)arachidonylamide
Rattus norvegicus
-
i.e. AM404, an anandamide uptake inhibitor, substrate of fatty acid amide hydrolase, EC 3.5.1.4, IC50 is 0.020 mM
0.00078
N-arachidonoyl dopamine
Homo sapiens
-
pH and temperature not specified in the publication
0.00014
N-arachidonoylmaleimide
Rattus norvegicus
IC50 value is 0.00014 mM
0.000155
N-arachidonyl maleimide
Homo sapiens
-
in 50 mM HEPES buffer, pH 8, 1 mM EDTA, and 10% dimethyl sulfoxide at 25°C for 60 min
0.0000091 - 6.64
N-arachidonylmaleimide
0.005 - 0.02
N-benzoylthiocarbamic cyclohexylethyl ester
0.051
N-cyclohexylmaleimide
Rattus norvegicus
IC50 value is 0.051 mM
0.0027 - 0.028
N-ethylmaleimide
0.413
N-hydroxymaleimide
Rattus norvegicus
IC50 value is 0.413 mM
0.00015
N-n-heptyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 150 nM
0.044
N-Phenylmaleimide
Rattus norvegicus
IC50 value is 0.044 mM
0.053
N-propylmaleimide
Rattus norvegicus
IC50 value is 0.053 mM
0.1
N-[3-(4-fluorophenyl)-6-oxopyrazolo[5,1-c]pyrido[4,3-e][1,2,4]triazin-7(6H)-yl]-2-(naphthalen-2-yloxy)acetamide
Homo sapiens
IC50 above 0.1 mM, pH and temperature not specified in the publication
0.00001
N-[4-(1,3-benzothiazol-2-yl)phenyl]-2-(1H-benzotriazol-1-yl)acetamide
Homo sapiens
pH and temperature not specified in the publication
0.053
NEM
Rattus norvegicus
IC50 value is 0.053 mM
0.036
noladin ether
Rattus norvegicus
-
IC50 value is 0.036 mM
0.00015
O-n-octyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 150 nM
0.00014
octane-1-sulfonyl fluoride
Mus musculus
-
-
0.00014
octyl sulfonyl fluoride
Mus musculus
-
IC50 is 140 nM
0.0023
paraoxon
Mus musculus
-
IC50 is 0.0023 mM
0.0023 - 0.0033
phenylmethylsulfonyl fluoride
0.000093 - 0.000398
pristimerin
0.004
pristimerol
Rattus norvegicus
-
purified MGL, at pH 7.5, 37°C
0.2
pseudorosmaricin
Homo sapiens
above, pH 7.2, temperature not specified in the publication
0.0000029
S-heptyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 2.9 nM
0.31
S-nonyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 0.31 nM
0.00000031
S-nonylbenzodioxaphosphorin oxide
Rattus norvegicus
-
cytosolic MAGL
0.0000031
S-pentyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 3.1 nM
0.031
SPB 01403
Rattus norvegicus
-
-
0.000051
stearyl benzodioxaphosphorin oxide
Mus musculus
-
IC50 is 51 nM
0.00046
tetrahydrolipstatin
Homo sapiens
-
-
0.00041 - 0.0011
troglitazone
0.028 - 0.075
[1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester
0.00048 - 0.0011
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
0.0000002
[4-[bis(1,3-benzodioxol-5-yl)methyl]-1-piperidinyl](1H-1,2,4-triazol-1-yl)methanone
Homo sapiens
at pH 7.4 and 37°C
additional information
additional information
Homo sapiens
-
-
-
0.0095
1-arachidonoylglycerol
Rattus norvegicus
-
IC50 value for the membraneous enzyme is 0.0095 mM, for the cytosolic enzyme 0.0071 mM, complete inhibition is possible
0.017
1-arachidonoylglycerol
Rattus norvegicus
-
inhibits the hydrolysis of cytosolic 2-oleoylglycerol, IC50 value is 0.017 mM, the affinity for the enzyme is highest with an arachidonyl side chain and decreases to fatty acids of shorter chain length
0.000151
2-octyl-4-isothiazolin-3-one
Rattus norvegicus
-
wild-type, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.000722
2-octyl-4-isothiazolin-3-one
Rattus norvegicus
-
mutant C208G, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.00021
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, without Triton X-100
0.0017
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, in the presence of 0.2% (m/v) Triton X-100
0.0037
4-nitrophenyl 4-[bis(1,3-benzodioxol-5-yl)hydroxymethyl]piperidine-1-carboxylate
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, in the presence of 0.2% (m/v) Triton X-100
0.01
alpha-methyl-1-arachidonoyl glycerol
Rattus norvegicus
-
cytosolic MAGL
0.015
alpha-methyl-1-arachidonoyl glycerol
Rattus norvegicus
-
cytosolic MAGL
0.071
alpha-methyl-1-arachidonoyl glycerol
Rattus norvegicus
-
membrane-bound MAGL
0.0000009
AM6701
Homo sapiens
-
native enzyme, in 50 mM Tris-HCl (pH 7.4) containing 8% DMSO, at room temperature
0.0000017
AM6701
Homo sapiens
-
recombinant enzyme, in 50 mM Tris-HCl (pH 7.4) containing 8% DMSO, at room temperature
0.0001
AM6702
Homo sapiens
-
native enzyme, in 50 mM Tris-HCl (pH 7.4) containing 8% DMSO, at room temperature
0.0028
AM6702
Homo sapiens
-
native enzyme, in 50 mM Tris-HCl (pH 7.4) containing 8% DMSO, at room temperature
0.0004
CAY10499
Homo sapiens
-
using 2-oleoylglycerol as a substrate
0.0005
CAY10499
Homo sapiens
-
using 4-nitophenyl acetate as a substrate
0.000034
chlorpyrifos oxon
Mus musculus
-
IC50 is 34 nM
0.000034
chlorpyrifos oxon
Rattus norvegicus
-
cytosolic MAGL
0.000003
ethyl octylphosphonofluoridate
Mus musculus
-
i.e. EOFP, n-C8H17P(O)(OC2H5)F, IC50 is 3.0 nM
0.000003
ethyl octylphosphonofluoridate
Rattus norvegicus
-
cytosolic MAGL
0.000315
euphol
Rattus norvegicus
-
purified MG, at pH 7.5, 37°CL
0.000882
euphol
Rattus norvegicus
-
nonpurified MGL, at pH 7.5, 37°C
0.0000054
methyl arachidonyl fluorophosphonate
Homo sapiens
pH 7.4, 22°C
0.000033
methyl arachidonyl fluorophosphonate
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, without Triton X-100
0.000062
methyl arachidonyl fluorophosphonate
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, in the presence of 0.2% (m/v) Triton X-100
0.00016
methyl arachidonyl fluorophosphonate
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, in the presence of 0.2% (m/v) Triton X-100
0.000003
methyl octylphosphonofluoridate
Mus musculus
-
i.e. MOFP, n-C8H17P(O)(OCH3)F, IC50 is 3.0 nM
0.000003
methyl octylphosphonofluoridate
Rattus norvegicus
-
cytosolic MAGL
0.0000091
N-arachidonylmaleimide
Homo sapiens
-
native enzyme, in 50 mM Tris-HCl (pH 7.4) containing 8% DMSO, at room temperature
0.00003
N-arachidonylmaleimide
Rattus norvegicus
-
wild-type, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.000046
N-arachidonylmaleimide
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/mlL bovine serum albumin, fatty acid-free
0.000107
N-arachidonylmaleimide
Rattus norvegicus
-
mutant C242G, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.00014
N-arachidonylmaleimide
Rattus norvegicus
-
membrane-bound MAGL
0.000442
N-arachidonylmaleimide
Rattus norvegicus
-
mutant C201G, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.0049
N-arachidonylmaleimide
Homo sapiens
-
using 2-oleoylglycerol as a substrate
0.0105
N-arachidonylmaleimide
Homo sapiens
-
using 4-nitophenyl acetate as a substrate
5.38
N-arachidonylmaleimide
Homo sapiens
mutant C201A, at 37°C for 10 min, pH 8.0, in 50 mM Tris buffer
6.11
N-arachidonylmaleimide
Homo sapiens
mutant C242A, at 37°C for 10 min, pH 8.0, in 50 mM Tris buffer
6.27
N-arachidonylmaleimide
Homo sapiens
wild-type, at 37°C for 10 min, pH 8.0, in 50 mM Tris buffer
6.48
N-arachidonylmaleimide
Homo sapiens
mutant C208A/C242A, at 37°C for 10 min, pH 8.0, in 50 mM Tris buffer
6.64
N-arachidonylmaleimide
Homo sapiens
mutant C208A, at 37°C for 10 min, pH 8.0, in 50 mM Tris buffer
0.005
N-benzoylthiocarbamic cyclohexylethyl ester
Homo sapiens
-
using 4-nitophenyl acetate as a substrate
0.02
N-benzoylthiocarbamic cyclohexylethyl ester
Homo sapiens
-
using 2-oleoylglycerol as a substrate
0.0027
N-ethylmaleimide
Rattus norvegicus
-
recombinant purified enzyme, for 10 min at 37°C, in 50 mM Tris-HCl, pH 8.0, 0.5 mg/ml bovine serum albumin, fatty acid-free
0.028
N-ethylmaleimide
Homo sapiens
-
-
0.0023
phenylmethylsulfonyl fluoride
Arabidopsis thaliana
pH 8.0-9.0, 37°C, recombinant enzyme
0.00235
phenylmethylsulfonyl fluoride
Arabidopsis thaliana
pH 8.0-9.0, 37°C, recombinant enzyme
0.0032
phenylmethylsulfonyl fluoride
Homo sapiens
versus 7-4-nitrophenylacetate, pH 8.0-9.0, 37°C, recombinant enzyme
0.0033
phenylmethylsulfonyl fluoride
Homo sapiens
versus 7-hydroxycoumarinyl arachidonate, pH 8.0-9.0, 37°C, recombinant enzyme
0.000093
pristimerin
Rattus norvegicus
-
purified MGL, at pH 7.5, 37°C
0.000398
pristimerin
Rattus norvegicus
-
nonpurified MGL, at pH 7.5, 37°C
0.00041
troglitazone
Rattus norvegicus
-
pH and temperature not specified in the publication
0.0011
troglitazone
Homo sapiens
-
pH and temperature not specified in the publication
0.0031
URB602
Homo sapiens
-
in 50 mM HEPES buffer, pH 8, 1 mM EDTA, and 10% dimethyl sulfoxide at 25°C for 60 min
0.0091
URB602
Homo sapiens
pH 7.4, 22°C
0.028
[1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester
Rattus norvegicus
-
cytosolic MAGL
0.075
[1,1'-biphenyl]-3-yl-carbamic acid, cyclohexyl ester
Rattus norvegicus
-
MAGL expressed in HeLa cells
0.00048
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, in the presence of 0.2% (m/v) Triton X-100
0.00061
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, without Triton X-100
0.0011
[4-(5-methoxy-2-oxo-1,3,4-oxadiazol-3-yl)-2-methylphenyl]carbamic acid benzyl ester
Homo sapiens
-
at 37°C, pH 7.0, incubation time of 15 min, in the presence of 0.2% (m/v) Triton X-100
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Karlsson, M.; Contreras, J.A.; Hellman, U.; Tornqvist, H.; Holm, C.
cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase
J. Biol. Chem.
272
27218-27223
1997
Mus musculus, Rattus norvegicus
brenda
Rindlisbacher, B.; Reist, M.; Zahler, P.
Diacylglycerol breakdown in plasma membranes of bovine chromaffin cells is a two-step mechanism mediated by diacylglycerol lipase and a monoacylglycerol lipase
Biochim. Biophys. Acta
905
349-357
1987
Bos taurus
brenda
Fredrikson, G.; Tornqvist, H.; Belfrage, P.
Hormone-sensitive lipase and monoacylglycerol lipase are both required for complete degradation of adipocyte triacylglycerol
Biochim. Biophys. Acta
876
288-293
1986
Rattus norvegicus
brenda
Errasfa, M.
Characterization of several phospholipase activities and diacylglycerol/2-monoacylglycerol lipases in rat alveolar macrophages
Biochim. Biophys. Acta
1085
201-208
1991
Rattus norvegicus
brenda
Keough, D.T.; de Jersey, J.; Zerner, B.
The relationship between the carboxylesterase and monoacylglycerol lipase activities of chicken liver microsomes
Biochim. Biophys. Acta
829
164-172
1985
Gallus gallus
brenda
Farooqui, A.A.; Taylor, W.A.; Horrocks, L.A.
Separation of bovine brain mono- and diacylglycerol lipases by Heparin Sepharose affinity chromatography
Biochem. Biophys. Res. Commun.
122
1241-1246
1984
Bos taurus
brenda
Somma-Delpero, C.; Valette, A.; Lepetit-Thevenin, J.; Nobili, O.; Boyer, J.; Verine, A.
Purification and properties of a monoacylglycerol lipase in human erythrocytes
Biochem. J.
312
519-525
1995
Homo sapiens
brenda
Konrad, R.J.; Major, C.D.; Wolf, B.A.
Diacylglycerol hydrolysis to arachidonic acid is necessary for insulin secretion from isolated pancreatic islets: sequential actions of diacylglycerol and monoacylglycerol lipases
Biochemistry
33
13284-13294
1994
Rattus norvegicus
brenda
Sakurada, T.; Noma, A.
Subcellular localization and some properties of monoacylglycerol lipase in rat adipocytes
J. Biochem.
90
1413-1419
1981
Rattus norvegicus
brenda
Khoo, J.C.; Steinberg, D.
Hormone-sensitive lipase from chicken adipose tissue including the separation and purification of monoglyceride lipase
Methods Enzymol.
71
627-636
1981
Gallus gallus
brenda
Tornqvist, H.; Belfrage, P.
Monoacylglycerol lipase from rat adipose tissue
Methods Enzymol.
71
647-652
1981
Rattus norvegicus
-
brenda
De Jong, B.J.P.; Kalkman, C.; Hulsmann, W.C.
Partial purification and properties of monoacylglycerol lipase and two esterases from isolated rat small intestinal epithelial cells
Biochim. Biophys. Acta
530
56-66
1978
Rattus norvegicus
brenda
Ikeda, Y.; Okamura, K.; Fujii, S.
Purification and characterization of rat liver microsomal monoacylglycerol lipase in comparison to the other esterases
Biochim. Biophys. Acta
488
128-139
1977
Rattus norvegicus
brenda
Farooqui, A.A.; Anderson, D.K.; Horrocks, L.A.
Effect of glutamate and its analogs on diacylglycerol and monoacylglycerol lipase activities of neuron-enriched cultures
Brain Res.
604
180-184
1993
Mus musculus
brenda
Yoneda, K.; Nishimura, T.; Katunuma, N.; Imamura, S.; Nitta, K.; Tsuge, H.
Crystallization and preliminary X-ray crystallographic studies of monoacylglycerol lipase of the moderately thermophilic Bacillus sp. H-257
Acta Crystallogr. Sect. D
58
1232-1233
2002
Bacillus subtilis, Bacillus subtilis H-257
brenda
Saario, S.M.; Savinainen, J.R.; Laitinen, J.T.; Jarvinen, T.; Niemi, R.
Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes
Biochem. Pharmacol.
67
1381-1387
2004
Rattus norvegicus
brenda
Monteiro, J.B.; Nascimento, M.G.; Ninow, J.L.
Lipase-catalyzed synthesis of monoacylglycerol in a homogeneous system
Biotechnol. Lett.
25
641-644
2003
Rhizomucor miehei
brenda
Dinh, T.P.; Freund, T.F.; Piomelli, D.
A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation
Chem. Phys. Lipids
121
149-158
2002
Rattus norvegicus
brenda
Eggert, T.; Pencreac'h, G.; Douchet, I.; Verger, R.; Jaeger, K.E.
A novel extracellular esterase from Bacillus subtilis and its conversion to a monoacylglycerol hydrolase
Eur. J. Biochem.
267
6459-6469
2000
Bacillus subtilis (Q79F14), Bacillus subtilis
brenda
Imamura, S.; Kitaura, S.
Purification and characterization of a monoacylglycerol lipase from the moderately thermophilic Bacillus sp. H-257
J. Biochem.
127
419-425
2000
Bacillus sp. (in: Bacteria), Bacillus sp. (in: Bacteria) H-257
brenda
Kitaura, S.; Suzuki, K.; Imamura, S.
Monoacylglycerol lipase from moderately thermophilic Bacillus sp. strain H-257: molecular cloning, sequencing, and expression in Escherichia coli of the gene
J. Biochem.
129
397-402
2001
Bacillus sp. (in: Bacteria) (P82597), Bacillus sp. (in: Bacteria), Bacillus sp. (in: Bacteria) H-257 (P82597)
brenda
Ito, M.; Tchoua, U.; Okamoto, M.; Tojo, H.
Purification and properties of a phospholipase A2/lipase preferring phosphatidic acid, bis(monoacylglycerol) phosphate, and monoacylglycerol from rat testis
J. Biol. Chem.
277
43674-43681
2002
Rattus norvegicus
brenda
Sakiyama, T.; Yoshimi, T.; Miyake, A.; Umeoka, M.; Tanaka, A.; Ozaki, S.; Nakanishi, K.
Purification and characterization of a monoacylglycerol lipase from Pseudomonas sp. LP7315
J. Biosci. Bioeng.
91
27-32
2001
Pseudomonas sp., Pseudomonas sp. LP7315
brenda
Sakiyama, T.; Yoshimi, T.; Tanaka, A.; Ozaki, S.; Nakanishi, K.
Analysis of monoglyceride synthetic reaction in a solvent-free two-phase system catalyzed by a monoacylglycerol lipase from Pseudomonas sp. LP7315
J. Biosci. Bioeng.
91
88-90
2001
Pseudomonas sp., Pseudomonas sp. LP7315
brenda
Dinh, T.P.; Carpenter, D.; Leslie, F.M.; Freund, T.F.; Katona, I.; Sensi, S.L.; Kathuria, S.; Piomelli, D.
Brain monoglyceride lipase participating in endocannabinoid inactivation
Proc. Natl. Acad. Sci. USA
99
10819-10824
2002
Rattus norvegicus (Q8R431)
brenda
Karlsson, M.; Tornqvist, H.; Holm, C.
Expression, purification, and characterization of histidine-tagged mouse monoglyceride lipase from baculovirus-infected insect cells
Protein Expr. Purif.
18
286-292
2000
Mus musculus
brenda
Vandevoorde, S.; Saha, B.; Mahadevan, A.; Razdan, R.K.; Pertwee, R.G.; Martin, B.R.; Fowler, C.J.
Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase
Biochem. Biophys. Res. Commun.
337
104-109
2005
Rattus norvegicus
brenda
Ghafouri, N.; Tiger, G.; Razdan, R.K.; Mahadevan, A.; Pertwee, R.G.; Martin, B.R.; Fowler, C.J.
Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol
Br. J. Pharmacol.
143
774-784
2004
Rattus norvegicus
brenda
Vandevoorde, S.; Fowler, C.J.
Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate
Br. J. Pharmacol.
145
885-893
2005
Rattus norvegicus
brenda
Saario, S.M.; Salo, O.M.; Nevalainen, T.; Poso, A.; Laitinen, J.T.; Jarvinen, T.; Niemi, R.
Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes
Chem. Biol.
12
649-656
2005
Rattus norvegicus (Q8R431)
brenda
Walter, L.; Dinh, T.; Stella, N.
ATP induces a rapid and pronounced increase in 2-arachidonoylglycerol production by astrocytes, a response limited by monoacylglycerol lipase
J. Neurosci.
24
8068-8074
2004
Mus musculus
brenda
Dinh, T.P.; Kathuria, S.; Piomelli, D.
RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol
Mol. Pharmacol.
66
1260-1264
2004
Homo sapiens, Rattus norvegicus
brenda
Quistad, G.B.; Klintenberg, R.; Caboni, P.; Liang, S.N.; Casida, J.E.
Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice
Toxicol. Appl. Pharmacol.
211
78-83
2006
Mus musculus
brenda
Cotes, K.; Dhouib, R.; Douchet, I.; Chahinian, H.; de Caro, A.; Carriere, F.; Canaan, S.
Characterization of an exported monoglyceride lipase from Mycobacterium tuberculosis possibly involved in the metabolism of host cell membrane lipids
Biochem. J.
408
417-427
2007
Mycobacterium tuberculosis, Mycobacterium tuberculosis H37Rv
brenda
Vila, A.; Rosengarth, A.; Piomelli, D.; Cravatt, B.; Marnett, L.J.
Hydrolysis of prostaglandin glycerol esters by the endocannabinoid-hydrolyzing enzymes, monoacylglycerol lipase and fatty acid amide hydrolase
Biochemistry
46
9578-9585
2007
Rattus norvegicus
brenda
Labar, G.; Bauvois, C.; Muccioli, G.G.; Wouters, J.; Lambert, D.M.
Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-arachidonoylglycerol signaling
Chembiochem
8
1293-1297
2007
Homo sapiens
brenda
Chon, S.H.; Zhou, Y.X.; Dixon, J.L.; Storch, J.
Intestinal monoacylglycerol metabolism: developmental and nutritional regulation of monoacylglycerol lipase and monoacylglycerol acyltransferase
J. Biol. Chem.
282
33346-33357
2007
Homo sapiens, Mus musculus, Mus musculus C57BL/6
brenda
Saario, S.M.; Poso, A.; Juvonen, R.O.; Jaervinen, T.; Salo-Ahen, O.M.
Fatty acid amide hydrolase inhibitors from virtual screening of the endocannabinoid system
J. Med. Chem.
49
4650-4656
2006
Homo sapiens, Rattus norvegicus
brenda
Hashimotodani, Y.; Ohno-Shosaku, T.; Kano, M.
Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus
J. Neurosci.
27
1211-1219
2007
Mus musculus, Mus musculus C57BL/6, Rattus norvegicus
brenda
Duncan, M.; Thomas, A.D.; Cluny, N.L.; Patel, A.; Patel, K.D.; Lutz, B.; Piomelli, D.; Alexander, S.P.; Sharkey, K.A.
Distribution and function of monoacylglycerol lipase in the gastrointestinal tract
Am. J. Physiol. Gastrointest. Liver Physiol.
295
G1255-G1265
2008
Mus musculus, Rattus norvegicus
brenda
Nomura, D.K.; Hudak, C.S.; Ward, A.M.; Burston, J.J.; Issa, R.S.; Fisher, K.J.; Abood, M.E.; Wiley, J.L.; Lichtman, A.H.; Casida, J.E.
Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels
Bioorg. Med. Chem. Lett.
18
5875-5878
2008
Mus musculus
brenda
Zvonok, N.; Pandarinathan, L.; Williams, J.; Johnston, M.; Karageorgos, I.; Janero, D.R.; Krishnan, S.C.; Makriyannis, A.
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis
Chem. Biol.
15
854-862
2008
Homo sapiens
brenda
Muccioli, G.G.; Labar, G.; Lambert, D.M.
CAY10499, a novel monoglyceride lipase inhibitor evidenced by an expeditious MGL assay
ChemBioChem
9
2704-2710
2008
Homo sapiens
brenda
Burston, J.J.; Sim-Selley, L.J.; Harloe, J.P.; Mahadevan, A.; Razdan, R.K.; Selley, D.E.; Wiley, J.L.
N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase
J. Pharmacol. Exp. Ther.
327
546-553
2008
Mus musculus
brenda
Zvonok, N.; Williams, J.; Johnston, M.; Pandarinathan, L.; Janero, D.R.; Li, J.; Krishnan, S.C.; Makriyannis, A.
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification
J. Proteome Res.
7
2158-2164
2008
Rattus norvegicus (Q8R431), Homo sapiens (Q99685), Homo sapiens
brenda
Holtfrerich, A.; Makharadze, T.; Lehr, M.
High-performance liquid chromatography assay with fluorescence detection for the evaluation of inhibitors against human recombinant monoacylglycerol lipase
Anal. Biochem.
399
218-224
2010
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Wang, Y.; Chanda, P.; Jones, P.G.; Kennedy, J.D.
A fluorescence-based assay for monoacylglycerol lipase compatible with inhibitor screening
Assay Drug Dev. Technol.
6
387-393
2008
Homo sapiens
brenda
Magrioti, V.; Naxakis, G.; Hadjipavlou-Litina, D.; Makriyannis, A.; Kokotos, G.
A novel monoacylglycerol lipase inhibitor with analgesic and anti-inflammatory activity
Bioorg. Med. Chem. Lett.
18
5424-5427
2008
Rattus norvegicus
brenda
King, A.R.; Lodola, A.; Carmi, C.; Fu, J.; Mor, M.; Piomelli, D.
A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of isothiazolinone-based enzyme inhibitors
Br. J. Pharmacol.
157
974-983
2009
Rattus norvegicus
brenda
King, A.R.; Dotsey, E.Y.; Lodola, A.; Jung, K.M.; Ghomian, A.; Qiu, Y.; Fu, J.; Mor, M.; Piomelli, D.
Discovery of potent and reversible monoacylglycerol lipase inhibitors
Chem. Biol.
16
1045-1052
2009
Rattus norvegicus
brenda
Labar, G.; Bauvois, C.; Borel, F.; Ferrer, J.L.; Wouters, J.; Lambert, D.M.
Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling
ChemBioChem
11
218-227
2010
Homo sapiens (Q99685), Homo sapiens
brenda
Vandevoorde, S.
Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors
Curr. Top. Med. Chem.
8
247-267
2008
Homo sapiens, Mus musculus, Rattus norvegicus
brenda
Bowman, A.L.; Makriyannis, A.
Refined homology model of monoacylglycerol lipase: toward a selective inhibitor
J. Comput. Aided Mol. Des.
23
799-806
2009
Homo sapiens (Q99685)
brenda
Feledziak, M.; Michaux, C.; Urbach, A.; Labar, G.; Muccioli, G.G.; Lambert, D.M.; Marchand-Brynaert, J.
beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase
J. Med. Chem.
52
7054-7068
2009
Homo sapiens
brenda
Heier, C.; Taschler, U.; Rengachari, S.; Oberer, M.; Wolinski, H.; Natter, K.; Kohlwein, S.D.; Leber, R.; Zimmermann, R.
Identification of Yju3p as functional orthologue of mammalian monoglyceride lipase in the yeast Saccharomyces cerevisiae
Biochim. Biophys. Acta
1801
1063-1071
2010
Saccharomyces cerevisiae
brenda
Bjoerklund, E.; Noren, E.; Nilsson, J.; Fowler, C.J.
Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays
Br. J. Pharmacol.
161
1512-1526
2010
Homo sapiens, Rattus norvegicus
brenda
Guindon, J.; Guijarro, A.; Piomelli, D.; Hohmann, A.G.
Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain
Br. J. Pharmacol.
163
1464-1478
2011
Rattus norvegicus
brenda
Nomura, D.K.; Long, J.Z.; Niessen, S.; Hoover, H.S.; Ng, S.W.; Cravatt, B.F.
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis
Cell
140
49-61
2010
Homo sapiens
brenda
Dhouib, R.; Laval, F.; Carriere, F.; Daffe, M.; Canaan, S.
A monoacylglycerol lipase from Mycobacterium smegmatis involved in bacterial cell interaction
J. Bacteriol.
192
4776-4785
2010
Mycolicibacterium smegmatis, Mycolicibacterium smegmatis mc(2)155 / ATCC 700084
brenda
Bertrand, T.; Auge, F.; Houtmann, J.; Rak, A.; Vallee, F.; Mikol, V.; Berne, P.; Michot, N.; Cheuret, D.; Hoornaert, C.; Mathieu, M.
Structural basis for human monoglyceride lipase inhibition
J. Mol. Biol.
396
663-673
2010
Homo sapiens
brenda
Freitas, L.; Paula, A.; dos Santos, J.; Zanin, G.; de Castro, H.
Enzymatic synthesis of monoglycerides by esterification reaction using Penicillium camembertii lipase immobilized on epoxy SiO2-PVA composite
J. Mol. Catal. B
65
87-90
2010
Penicillium camemberti
-
brenda
Keimpema, E.; Barabas, K.; Morozov, Y.M.; Tortoriello, G.; Torii, M.; Cameron, G.; Yanagawa, Y.; Watanabe, M.; Mackie, K.; Harkany, T.
Differential subcellular recruitment of monoacylglycerol lipase generates spatial specificity of 2-arachidonoyl glycerol signaling during axonal pathfinding
J. Neurosci.
30
13992-14007
2010
Mus musculus
brenda
Karageorgos, I.; Tyukhtenko, S.; Zvonok, N.; Janero, D.R.; Sallum, C.; Makriyannis, A.
Identification by nuclear magnetic resonance spectroscopy of an active-site hydrogen-bond network in human monoacylglycerol lipase (hMGL): implications for hMGL dynamics, pharmacological inhibition, and catalytic mechanism
Mol. Biosyst.
6
1381-1388
2010
Homo sapiens
brenda
Chanda, P.K.; Gao, Y.; Mark, L.; Btesh, J.; Strassle, B.W.; Lu, P.; Piesla, M.J.; Zhang, M.Y.; Bingham, B.; Uveges, A.; Kowal, D.; Garbe, D.; Kouranova, E.V.; Ring, R.H.; Bates, B.; Pangalos, M.N.; Kennedy, J.D.; Whiteside, G.T.; Samad, T.A.
Monoacylglycerol lipase activity is a critical modulator of the tone and integrity of the endocannabinoid system
Mol. Pharmacol.
78
996-1003
2010
Mus musculus
brenda
Jermsuntiea, W.; Aki, T.; Toyoura, R.; Iwashita, K.; Kawamoto, S.; Ono, K.
Purification and characterization of intracellular lipase from the polyunsaturated fatty acid-producing fungus Mortierella alliacea
New Biotechnol.
28
158-164
2011
Mortierella alliacea, Mortierella alliacea YN-15
brenda
Schalk-Hihi, C.; Schubert, C.; Alexander, R.; Bayoumy, S.; Clemente, J.C.; Deckman, I.; DesJarlais, R.L.; Dzordzorme, K.C.; Flores, C.M.; Grasberger, B.; Kranz, J.K.; Lewandowski, F.; Liu, L.; Ma, H.; Maguire, D.; Macielag, M.J.; McDonnell, M.E.; Mezzasalma Haarlander, T.; Miller, R.; Milligan, C.; R, R.e.
Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 A resolution
Protein Sci.
20
670-683
2011
Homo sapiens (Q99685), Homo sapiens
brenda
Karageorgos, I.; Wales, T.E.; Janero, D.R.; Zvonok, N.; Vemuri, V.K.; Engen, J.R.; Makriyannis, A.
Active-site inhibitors modulate the dynamic properties of human monoacylglycerol lipase: a hydrogen exchange mass spectrometry study
Biochemistry
52
5016-5026
2013
Homo sapiens
brenda
Rengachari, S.; Bezerra, G.A.; Riegler-Berket, L.; Gruber, C.C.; Sturm, C.; Taschler, U.; Boeszoermenyi, A.; Dreveny, I.; Zimmermann, R.; Gruber, K.; Oberer, M.
The structure of monoacylglycerol lipase from Bacillus sp. H257 reveals unexpected conservation of the cap architecture between bacterial and human enzymes
Biochim. Biophys. Acta
1821
1012-1021
2012
Bacillus sp. (in: Bacteria) (P82597), Bacillus sp. (in: Bacteria), Bacillus sp. (in: Bacteria) H-257 (P82597)
brenda
Afzal, O.; Kumar, S.; Kumar, R.; Firoz, A.; Jaggi, M.; Bawa, S.
Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors
Bioorg. Med. Chem. Lett.
24
3986-3996
2014
Homo sapiens (Q99685), Homo sapiens
brenda
Li, C.; Vilches-Flores, A.; Zhao, M.; Amiel, S.A.; Jones, P.M.; Persaud, S.J.
Expression and function of monoacylglycerol lipase in mouse beta-cells and human islets of Langerhans
Cell. Physiol. Biochem.
30
347-358
2012
Homo sapiens, Mus musculus
brenda
Cao, Z.; Mulvihill, M.M.; Mukhopadhyay, P.; Xu, H.; Erdelyi, K.; Hao, E.; Holovac, E.; Hasko, G.; Cravatt, B.F.; Nomura, D.K.; Pacher, P.
Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice
Gastroenterology
144
808-817.e15
2013
Mus musculus
brenda
Rengachari, S.; Aschauer, P.; Schittmayer, M.; Mayer, N.; Gruber, K.; Breinbauer, R.; Birner-Gruenberger, R.; Dreveny, I.; Oberer, M.
Conformational plasticity and ligand binding of bacterial monoacylglycerol lipase
J. Biol. Chem.
288
31093-31104
2013
Bacillus sp. (in: Bacteria) (P82597), Bacillus sp. (in: Bacteria), Bacillus sp. (in: Bacteria) H-257 (P82597)
brenda
Tsurumura, T.; Tsuge, H.
Substrate selectivity of bacterial monoacylglycerol lipase based on crystal structure
J. Struct. Funct. Genomics
15
83-89
2014
Bacillus sp. (in: Bacteria) (P82597), Bacillus sp. (in: Bacteria), Bacillus sp. (in: Bacteria) H-257 (P82597)
brenda
Laitinen, T.; Navia-Paldanius, D.; Rytilahti, R.; Marjamaa, J.J.; Ka?izkova, J.; Parkkari, T.; Pantsar, T.; Poso, A.; Laitinen, J.T.; Savinainen, J.R.
Mutation of Cys242 of human monoacylglycerol lipase disrupts balanced hydrolysis of 1- and 2-monoacylglycerols and selectively impairs inhibitor potency
Mol. Pharmacol.
85
510-519
2014
Homo sapiens
brenda
Savinainen, J.R.; Kansanen, E.; Pantsar, T.; Navia-Paldanius, D.; Parkkari, T.; Lehtonen, M.; Laitinen, T.; Nevalainen, T.; Poso, A.; Levonen, A.L.; Laitinen, J.T.
Robust hydrolysis of prostaglandin glycerol esters by human monoacylglycerol lipase (MAGL)
Mol. Pharmacol.
86
522-535
2014
Homo sapiens (Q99685), Homo sapiens
brenda
Chon, S.H.; Douglass, J.D.; Zhou, Y.X.; Malik, N.; Dixon, J.L.; Brinker, A.; Quadro, L.; Storch, J.
Over-expression of monoacylglycerol lipase (MGL) in small intestine alters endocannabinoid levels and whole body energy balance, resulting in obesity
PLoS ONE
7
e43962
2012
Mus musculus
brenda
Chen, H.; Tian, R.; Ni, Z.; Zhang, Z.; Chen, H.; Guo, Q.; Saier, M.H.
Conformational transition pathway in the inhibitor binding process of human monoacylglycerol lipase
Protein J.
33
503-511
2014
Homo sapiens
brenda
Lauria, S.; Casati, S.; Ciuffreda, P.
Synthesis and characterization of a new fluorogenic substrate for monoacylglycerol lipase and application to inhibition studies
Anal. Bioanal. Chem.
407
8163-8167
2015
Homo sapiens (Q99685), Homo sapiens
brenda
Kim, R.; Suh, M.
The GxSxG motif of Arabidopsis monoacylglycerol lipase (MAGL6 and MAGL8) is essential for their enzyme activities
Appl. Biol. Chem.
59
833-840
2016
Arabidopsis thaliana (O49284), Arabidopsis thaliana (O80959), Arabidopsis thaliana (Q8H133), Homo sapiens (Q99685)
-
brenda
De Leo, M.; Huallpa, C.G.; Alvarado, B.; Granchi, C.; Poli, G.; De Tommasi, N.; Braca, A.
New diterpenes from Salvia pseudorosmarinus and their activity as inhibitors of monoacylglycerol lipase (MAGL)
Fitoterapia
130
251-258
2018
Homo sapiens (Q99685)
brenda
Kishimoto, Y.; Cagniard, B.; Yamazaki, M.; Nakayama, J.; Sakimura, K.; Kirino, Y.; Kano, M.
Task-specific enhancement of hippocampus-dependent learning in mice deficient in monoacylglycerol lipase, the major hydrolyzing enzyme of the endocannabinoid 2-arachidonoylglycerol
Front. Behav. Neurosci.
9
134
2015
Mus musculus (O35678), Mus musculus C57BL/6N (O35678)
brenda
Tyukhtenko, S.; Karageorgos, I.; Rajarshi, G.; Zvonok, N.; Pavlopoulos, S.; Janero, D.R.; Makriyannis, A.
Specific inter-residue interactions as determinants of human monoacylglycerol lipase catalytic competency a role for global conformational chanages
J. Biol. Chem.
291
2556-2565
2016
Homo sapiens (Q99685), Homo sapiens
brenda
Xiang, W.; Shi, R.; Kang, X.; Zhang, X.; Chen, P.; Zhang, L.; Hou, A.; Wang, R.; Zhao, Y.; Zhao, K.; Liu, Y.; Ma, Y.; Luo, H.; Shang, S.; Zhang, J.; He, F.; Yu, S.; Gan, L.; Shi, C.; Li, Y.; Yang, W.; Liang, H.; Miao, H.
Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression
Nat. Commun.
9
2574
2018
Mus musculus (O35678), Homo sapiens (Q99685), Homo sapiens
brenda
Kim, R.J.; Kim, H.J.; Shim, D.; Suh, M.C.
Molecular and biochemical characterizations of the monoacylglycerol lipase gene family of Arabidopsis thaliana
Plant J.
85
758-771
2016
Arabidopsis thaliana, Arabidopsis thaliana (O23179), Arabidopsis thaliana (O23180), Arabidopsis thaliana (O23181), Arabidopsis thaliana (O48723), Arabidopsis thaliana (O49284), Arabidopsis thaliana (O80959), Arabidopsis thaliana (Q8H133), Arabidopsis thaliana (Q93ZQ3), Arabidopsis thaliana (Q9FIY1), Arabidopsis thaliana (Q9SV43)
brenda
Beladjila, K.A.; Berrehal, D.; De Tommasi, N.; Granchi, C.; Bononi, G.; Braca, A.; De Leo, M.
New phenylethanoid glycosides from Cistanche phelypaea and their activity as inhibitors of monoacylglycerol lipase (MAGL)
Planta Med.
84
710-715
2018
Homo sapiens (Q99685)
brenda
Berdan, C.A.; Erion, K.A.; Burritt, N.E.; Corkey, B.E.; Deeney, J.T.
Inhibition of monoacylglycerol lipase activity decreases glucose-stimulated insulin secretion in INS-1 (832/13) cells and rat islets
PLoS ONE
11
e0149008
2016
Rattus norvegicus (Q8R431), Rattus norvegicus Sprague-Dawley (Q8R431)
brenda
Aschauer, P.; Zimmermann, R.; Breinbauer, R.; Pavkov-Keller, T.; Oberer, M.
The crystal structure of monoacylglycerol lipase from M. tuberculosis reveals the basis for specific inhibition
Sci. Rep.
8
8948
2018
Mycobacterium tuberculosis (O07427), Mycobacterium tuberculosis, Mycobacterium tuberculosis H37Rv (O07427), Mycobacterium tuberculosis ATCC 25618 (O07427)
brenda